8/8/01

```
Set     Items   Description
S1      10515   COACERVATE OR COACERVATION
S2      74108   S1 AND MICROPARTICLE? OR MICROCAPSULE?
S3       5051   S2 AND S1
S4        607   S3 AND BIODEGRADABLE
S5        199   S4 AND ANTIGEN
S6         65   S5 NOT PY>1998
S7         65   RD (unique items)
S8       8644   S7 AND COACERVATE OR COACERVATION
S9         65   S8 AND S7
S10         0   KWIC S9
? d kwic s9

>>>'9' valid only in keyword format
? d kwic

>>>KWIC option is not available in file(s): 399
>>>Item 1 is not within valid item range for file 16
? s9 kwic

     S11       0  9 KWIC
? set hi on

Hilight option is not available in file(s) 399
HILIGHT set on as '%'
? t s9/3,ab/1-4

>>>No matching display code(s) found in file(s): 65, 342, 345, 764

 9/3,AB/1     (Item 1 from file: 654)
DIALOG(R)File 654:US PAT.FULL.
(c) format only 2001 The Dialog Corp. All rts. reserv.

             02893542
Utility
METHODS FOR THE DIAGNOSIS OF GLAUCOMA

PATENT NO.:  5,854,415
ISSUED:      December 29, 1998 (19981229)
INVENTOR(s): Nguyen, Thai D., Mill Valley, CA (California), US (United
             States of America)
             Polansky, Jon R., Mill Valley, CA (California), US (United
             States of America)
             Huang, Weidong, San Francisco, CA (California), US (United
             States of America)
ASSIGNEE(s): The Regents of the University of California, (A U.S. Company
             or Corporation), Oakland, CA (California), US (United States
             of America)
             [Assignee Code(s): 13234]
APPL. NO.:   8-882,238
FILED:       June 25, 1997 (19970625)
```

CROSS REFERENCE TO RELATED APPLICATION

This application is a divisional of U.S. patent application Ser. No. 08-649,432, filed May 17, 1996 U.S. Pat. No. 5,789,169, which is a continuation-in-part of U.S. patent application Ser. No. 08-546,568, filed Oct. 20, 1995, which is a continuation-in-part of U.S. patent application Ser. No. 08-336,235, filed Nov. 3, 1994, which is now U.S. Pat. No. 5,606,043. This application is also a divisional of U.S. patent application

Ser. No. 08-649,432, filed May 17, 1996 U.S. Pat. No. 5,789,169, which is a continuation-in-part of U.S. patent application Ser. No. 08-336,235, filed Nov. 3, 1994, which is now U.S. Pat. No. 5,606,043.

FIELD OF THE INVENTION

The present invention is in the fields of diagnostics, and concerns methods and reagents for diagnosing glaucoma and related disorders. This invention was supported with Government funds (NIH EY02477 and NIH EY 08905-02). The Government has certain rights in this invention.

FULL TEXT: 1532 lines

ABSTRACT

A glucocorticoid-induced protein, TIGR, that is produced by cells of the trabeclar meshwork can be used to diagnose glaucoma. The TIGR protein, anti-TIGR antibodies, and TIGR encoding sequences also provide a diagnostic for glaucoma and its related diseases.

9/3,AB/2 (Item 2 from file: 654)
DIALOG(R)File 654:US PAT.FULL.

02888348

Utility
METHODS FOR THE DIAGNOSIS OF GLAUCOMA

PATENT NO.: 5,849,879
ISSUED: December 15, 1998 (19981215)
INVENTOR(s): Nguyen, Thai D., Mill Valley, CA (California), US (United States of America)
Polansky, Jon R., Mill Valley, CA (California), US (United States of America)
Huang, Weidong, Irvine, CA (California), US (United States of America)
ASSIGNEE(s): The Regents of the University of California, (A U.S. Company or Corporation), Oakland, CA (California), US (United States of America)
[Assignee Code(s): 13234]
APPL. NO.: 8-645,900
FILED: May 14, 1996 (19960514)

CROSS REFERENCE TO RELATED APPLICATION

This application is a continuation-in-part of U.S. patent application Ser. No. 08-546,568, filed Oct. 20, 1995, pending which is a continuation-in-part of U.S. application Ser. No 08-336,235, filed Nov. 3, 1994, now U.S. Pat. No. 5,606,043.

FIELD OF THE INVENTION

The present invention is in the fields of diagnostics, and concerns methods and reagents for diagnosing glaucoma and related disorders. This invention was supported with Government funds (NIH EY02477 and NIH EY 08905-02). The Government has certain rights in this invention.

FULL TEXT: 1514 lines

ABSTRACT

A glucocorticoid-induced protein, TIGR, that is produced by cells of the trabecular meshwork can be used to diagnose glaucoma. The TIGR protein, anti-TIGR antibodies, and TIGR encoding sequences also provide a diagnostic for glaucoma and its related diseases.

9/3,AB/3 (Item 3 from file: 654)
DIALOG(R)File 654:US PAT.FULL.

02860202

Utility
BIOCOMPATIBLE OCULAR IMPLANTS
[Method for treating an eye condition]

PATENT NO.: 5,824,072
ISSUED: October 20, 1998 (19981020)
INVENTOR(s): Wong, Vernon G., Rockville, MD (Maryland), US (United States of America)
ASSIGNEE(s): Oculex Pharmaceuticals, Inc , (A U.S. Company or Corporation), Sunnyvale, CA (California), US (United States of America)
[Assignee Code(s): 41997]
APPL. NO.: 8-698,238
FILED: August 14, 1996 (19960814)

This is a continuation of application Ser. No. 08-437,573 filed May 9, 1995 now abandoned, which is a continuation of application Ser. No. 08-153,184 filed Nov. 15, 1993, now U.S. Pat. No. 5,443,505.

FULL TEXT: 992 lines

ABSTRACT

Implants comprising active agents are employed for introduction into a suprachoroidal space or an avascular region of an eye for therapeutic purposes. The administration of drugs is controlled and maintained for long periods of time, while ensuring the substantial absence of significant levels outside the site of administration.

9/3,AB/4 (Item 4 from file: 654)
DIALOG(R)File 654:US PAT.FULL.

02842710

Utility
PREPARATION OF IONICALLY CROSS-LINKED POLYPHOSPHAZENE MICROSPHERESY BY %COACERVATION%
[Controlling particle size distribution]

PATENT NO.: 5,807,757
ISSUED: September 15, 1998 (19980915)
INVENTOR(s): Andrianov, Alexander K., Belmont, MA (Massachusettes), US (United States of America)
Chen, Jianping, Lexington, MA (Massachusettes), US (United States of America)
ASSIGNEE(s): Virus Research Institute, Inc , (A U.S. Company or Corporation), Cambridge, MA (Massachusetts), US (United States of America)
[Assignee Code(s): 38169]
APPL. NO.: 8-675,713
FILED: July 02, 1996 (19960702)

FULL TEXT: 557 lines

ABSTRACT

A method is provided for preparing polyphosphazene microspheres wherein the polyphosphazene microspheres are produced by %coacervation%. A solution containing a polyphosphazene is admixed with a solution containing a salt of a monovalent ion such as a salt of a Group I element (for example, NaCl) to form a dispersion containing polyphosphazene %coacervate% microdroplets. The dispersion then is admixed with a solution containing a salt of a multivalent ion, such as a salt of a Group II element (for example, CaCl sub 2) to form a suspension of polyphosphazene microspheres. The polyphosphazene microspheres then are recovered from the suspension. Such method enables one to obtain high yields of microspheres having a controlled size distribution. Polyphosphazene microspheres containing biological material can be produced by providing a biological material in the polyphosphazene solution that is mixed with the solution containing a salt of a monovalent ion. The biological material may be an %antigen% or other biological material selected from proteins, nucleic acids, polysaccharides and synthetic compounds having biological activity.

>No matching display code(s) found in file(s): 65, 342, 345, 764

9/3,AB/5 (Item 5 from file: 654)
DIALOG(R)File 654:US PAT.FULL.

02822670
Utility
METHODS FOR THE DIAGNOSIS OF GLAUCOMA
[Using a glucocorticoid induced protein]

PATENT NO.: 5,789,169
ISSUED: August 04, 1998 (19980804)
INVENTOR(s): Nguyen, Thai D., Mill Valley, CA (California), US (United States of America)
Polansky, Jon R., Mill Valley, CA (California), US (United States of America)
Huang, Weidong, Irvine, CA (California), US (United States of America)
ASSIGNEE(s): Regents of the University of California, (A U.S. Company or Corporation), Oakland, CA (California), US (United States of America)
[Assignee Code(s): 13234]
APPL. NO.: 8-649,432
FILED: May 17, 1996 (19960517)

CROSS REFERENCE TO RELATED APPLICATION

This application is a continuation-in-part of U.S. patent application Ser. No. 08-546,568, filed Oct. 20, 1995, which is a continuation-in-part of U.S. application Ser. No. 08-336,235, filed Nov. 3, 1994 U.S. Pat. No. 5,606,043. This application is also a continuation-in-part of U.S. application Ser. No. 08-336,235, filed Nov. 3, 1994 U.S. Pat. No. 5,606,043.

FULL TEXT: 1949 lines

ABSTRACT

A glucocorticoid-induced protein, TIGR, that is produced by cells of the trabecular meshwork can be used to diagnose glaucoma. The TIGR protein, anti-TIGR antibodies, and TIGR encoding sequences also provide a diagnostic for glaucoma and its related disease.

9/3,AB/6 (Item 6 from file: 654)
DIALOG(R)File 654:US PAT.FULL.

02799052
Utility
BIOCOMPATIBLE OCULAR IMPLANTS
[Method for treating an eye condition]

PATENT NO.: 5,766,242
ISSUED: June 16, 1998 (19980616)
INVENTOR(s): Wong, Vernon G., Rockville, MD (Maryland), US (United States of America)

Kochinke, Frank, San Jose, CA (California), US (United States of America)
ASSIGNEE(s): Oculex Pharmaceuticals, Inc , (A U.S. Company or Corporation), Sunnyvale, CA (California), US (United States of America) [Assignee Code(s): 41997]
APPL. NO.: 8-615,640
FILED: March 13, 1996 (19960313)

This is a continuation of application Ser. No. 08-431,098 filed 28 Apr., 1995 now abandoned, which is a continuation of 08-153,184 filed 15 Nov., 1993, now U.S. Pat. No. 5,443,505.

FULL TEXT: 950 lines

ABSTRACT

Implants comprising active agents are employed for introduction into a suprachoroidal space or an avascular region of an eye for therapeutic purposes. The administration of drugs is controlled and maintained for long periods of time, while ensuring the substantial absence of significant levels outside the site of administration.

9/3,AB/7 (Item 7 from file: 654)
DIALOG(R)File 654:US PAT.FULL.

02710833
Utility
%MICROCAPSULES% OF PREDETERMINED PEPTIDE(S) SPECIFICITY (IES), THEIR PREPARATION AND USES

PATENT NO.: 5,686,113
ISSUED: November 11, 1997 (19971111)
INVENTOR(s): Speaker, Tully J., Philadelphia, PA (Pennsylvania), US (United States of America)
Sultzbaugh, Kenneth J., Philadelphia, PA (Pennsylvania), US (United States of America)
ASSIGNEE(s): Temple University of the Commonwealth System of Higher Education, (A U.S. Company or Corporation), Philadelphia, PA (Pennsylvania), US (United States of America) [Assignee Code(s): 83508]
APPL. NO.: 8-408,052
FILED: March 21, 1995 (19950321)

FULL TEXT: 1640 lines

ABSTRACT
An aqueous core %microcapsule% has a capsular wall provided with a peptide(s) of pre-determined binding specificity(ies) appended to the surface, the wall being the reaction product of an anionic polymer or salt thereof and a polyamine, salt thereof, mixtures thereof, or mixtures thereof with monoamines. The aqueous core may contain an active ingredient(s), and be targeted for delivery to specific cell tissues. The %microcapsules% are provided as a composition and in a kit with instructions for use in imaging, diagnosis, therapy, vaccination, and other applications.

9/3,AB/8 (Item 8 from file: 654)
DIALOG(R)File 654:US PAT.FULL.

02698233
Utility

METHOD FOR THE TREATMENT OF A TRABECULAR MESHWORK WHOSE CELLS ARE SUBJECT TO INHIBITION OF CELL DIVISION
[Administering to a human an ophthalmologically effective nonsteroidal cyclooxygenase inhibitor and a carrier to increase mitosis; glaucoma; aging; stresses due to environment, oxidation, phagocytosis or glucocorticoids]

PATENT NO.: 5,674,888
ISSUED: October 07, 1997 (19971007)
INVENTOR(s): Polansky, Jon R., Mill Valley, CA (California), US (United States of America)
Bloom, Ernest, Alamo, CA (California), US (United States of America)
Fauss, Donald J., San Francisco, CA (California), US (United States of America)
ASSIGNEE(s): University of California, (A U.S. Company or Corporation), Alameda, CA (California), US (United States of America)
[Assignee Code(s): 13234]
APPL. NO.: 8-486,255
FILED: June 07, 1995 (19950607)

The present invention is in the field of therapeutics, and concerns methods and reagents for enhancing the mitotic rate of the cells of a trabecular meshwork whose cells are subject to an inhibition in cell division. This invention was supported with Government funds (NIH EY02477 and NIH EY 08905-02). The Government has certain rights in this invention.

FULL TEXT: 1117 lines

ABSTRACT

The invention concerns the recognition that certain non-steroidal anti-inflammatory agents can overcome or ameliorate limitations on trabecular meshwork cell division produced by environmental stresses (e.g., oxidative or phagocytic injury, or glucocorticoid exposure), and thus can be used to prevent or treat loss of trabecular cells found in certain forms of glaucoma and in normal aging. The use of such non-steroidal anti-inflammatory agents can ameliorate the severity, or prevent glaucoma.

9/3,AB/9 (Item 9 from file: 654)
DIALOG(R)File 654:US PAT.FULL.

02663061
Utility
METHODS AND COMPOSITIONS FOR MICROENCAPSULATION OF ADJUVANTS
[Polylactide or polylactide-glycolide copolymer]

PATENT NO.: 5,643,605
ISSUED: July 01, 1997 (19970701)
INVENTOR(s): Cleland, Jeffrey L., San Carlos, CA (California), US (United States of America)
Lim, Amy, San Bruno, CA (California), US (United States of America)
Powell, Michael Frank, San Francisco, CA (California), US (United States of America)
ASSIGNEE(s): Genentech, Inc, (A U.S. Company or Corporation), South San Francisco, CA (California), US (United States of America)
[Assignee Code(s): 7579]
APPL. NO.: 8-460,363
FILED: June 02, 1995 (19950602)

This application is a continuation of application Ser. No. 08-143,332,

filed Oct. 25, 1993 now abandoned.

FULL TEXT: 1731 lines

ABSTRACT

Methods and compositions are provided for the encapsulation of adjuvants in PLGA microspheres for use as vaccines. Mixtures of microspheres are provided which release adjuvant at desired intervals to provide boosts with adjuvant.

9/3,AB/10 (Item 10 from file: 654)
DIALOG(R)File 654:US PAT.FULL.

02623272
Utility
METHODS FOR THE DIAGNOSIS OF GLAUCOMA
[Specific nucleic acid encoded human trabecular meshwork induced glucocorticoid response protein]

PATENT NO.: 5,606,043
ISSUED: February 25, 1997 (19970225)
INVENTOR(s): Nguyen, Thai D., Mill Valley, CA (California), US (United States of America)
Polansky, Jon R., Mill Valley, CA (California), US (United States of America)
Huang, Weidong, San Francisco, CA (California), US (United States of America)
ASSIGNEE(s): The Regents of the University of California, (A U.S. Company or Corporation), Oakland, CA (California), US (United States of America)
[Assignee Code(s): 13234]
APPL. NO.: 8-336,235
FILED: November 03, 1994 (19941103)

FIELD OF THE INVENTION

The present invention is in the fields of diagnostics, and concerns methods and reagents for diagnosing glaucoma and related disorders. This invention was supported with Government funds (NIH EY02477 and NIH EY 08905-02). The Government has certain rights in this invention.

FULL TEXT: 1303 lines

ABSTRACT

A glucocorticoid-induced protein, TIGR, that is produced by cells of the trabecular meshwork can be used to diagnose glaucoma. The TIGR protein, anti-TIGR antibodies, and TIGR encoding sequences also provide a diagnostic for glaucoma and its related diseases.

>>No matching display code(s) found in file(s): 65, 342, 345, 764

9/3,AB/11 (Item 11 from file: 654)
DIALOG(R)File 654:US PAT.FULL.

02616460
Utility
METHODS FOR THE CYTO-PROTECTION OF THE TRABECULAR MESHWORK
[Administering a non-steroidal antiinflammatory agent preventing cell lose in eye disorders]

PATENT NO.: 5,599,535
ISSUED: February 04, 1997 (19970204)
INVENTOR(s): Polansky, Jon R., Mill Valley, CA (California), US (United States of America)
Bloom, Ernest, Alamo, CA (California), US (United States of America)
Fauss, Donald J., San Francisco, CA (California), US (United States of America)
ASSIGNEE(s): Regents of the University of California, (A U.S. Company or Corporation), Oakland, CA (California), US (United States of America)
[Assignee Code(s): 13234]
APPL. NO.: 8-479,185
FILED: June 07, 1995 (19950607)

FIELD OF THE INVENTION

The present invention is in the field of therapeutics, and concerns methods and reagents for protecting the cells of the trabecular meshwork from agents or processes that would otherwise result in trabecular cell loss. This invention was supported with Government funds (NIH EY02477 and NIH EY 08905-02). The Government has certain rights in this invention.

FULL TEXT: 1164 lines

ABSTRACT

The invention concerns the recognition that certain non-steroidal anti-inflammatory agents produce cytoprotective effects on trabecular cells, and thus can be used to prevent injury to the cells and treat the loss of trabecular cells caused by oxidative or other forms of injury to the cells. Such treatment can ameliorate the severity, or prevent, glaucoma.

9/3,AB/12 (Item 12 from file: 654)
DIALOG(R)File 654:US PAT.FULL.

02581900
Utility
SYNTHETIC GANGLIOSIDE DERIVATIVES
[Immunosuppersant]

PATENT NO.: 5,567,684
ISSUED: October 22, 1996 (19961022)
INVENTOR(s): Ladisch, Stephan, Chevy Chase, MD (Maryland), US (United

States of America)
Hasegawa, Akira, Gifu, JP (Japan)
ASSIGNEE(s): The Regents of The University of California, (A U.S. Company or Corporation), Oakland, CA (California), US (United States of America)
[Assignee Code(s): 13234]
APPL. NO.: 8-305,832
FILED: September 14, 1994 (19940914)

FULL TEXT: 980 lines

ABSTRACT

Synthetic compounds which are useful for suppressing an immune response are disclosed. The synthetic compounds have the formula [See structure in original document] wherein A is a carbohydrate moiety which corresponds to the carbohydrate moiety of a naturally occurring ganglioside, n is 5 to 20 and m is to 20. Also presented are methods for suppressing an immune response in an animal and compositions of matter employing the compounds as shown above.

9/3,AB/13 (Item 13 from file: 654)
DIALOG(R)File 654:US PAT.FULL.

02545335

Utility
METHOD OF PRODUCING SUSTAINED-RELEASE PREPARATION
[Allowing water soluble polypeptide to diffuse into matrix of lactic acid-glycolic acid copolymer]

PATENT NO.: 5,534,269
ISSUED: July 09, 1996 (19960709)
INVENTOR(s): Igari, Yasutaka, Kobe, JP (Japan)
Yamamoto, Kazumichi, Nara, JP (Japan)
Okamoto, Kayoko, Osaka, JP (Japan)
Yamagata, Yutaka, Kobe, JP (Japan)
ASSIGNEE(s): Takeda Chemical Industries, Ltd, (A Non-U.S. Company or Corporation), Osaka, JP (Japan)
[Assignee Code(s): 82624]
APPL. NO.: 8-270,838
FILED: July 05, 1994 (19940705)
PRIORITY: 5-165793, JP (Japan), July 5, 1993 (19930705)
6-081765, JP (Japan), April 20, 1994 (19940420)

FULL TEXT: 1345 lines

ABSTRACT

A method of producing a sustained-release preparation which includes permitting a water-soluble polypeptide to permeate into a %biodegradable% matrix in the aqueous solution. The production method of the present invention makes possible the permeation of a water-soluble polypeptide into a %biodegradable% matrix without bringing the water-soluble polypeptide into contact with an organic solvent. Hence the water-soluble polypeptide is prepared without affecting the water-soluble polypeptide bioactivity and is thus effective for use as a pharmaceutical.

9/3,AB/14 (Item 14 from file: 654)
DIALOG(R)File 654:US PAT.FULL.

02453521

Utility
METHODS AND COMPOSITIONS FOR THE ORAL DELIVERY OF THERAPEUTIC AGENTS

[Polyacrylic acid, crosslinked alginate]

PATENT NO.: 5,451,411
ISSUED: September 19, 1995 (19950919)
INVENTOR(s): Gombotz, Wayne R., Kirkland, WA (Washington), US (United States of America)
Mumper, Russell J., Greenville, NC (North Carolina), US (United States of America)
Hoffman, Allan S., Seattle, WA (Washington), US (United States of America)
Bouchard, Lisa S., Renton, WA (Washington), US (United States of America)
ASSIGNEE(s): Bristol Myers Squibb Company, (A U.S. Company or Corporation), New York, NY (New York), US (United States of America)
University of Washington, (A U.S. Company or Corporation), Seattle, WA (Washington), US (United States of America)
[Assignee Code(s): 2937; 22921]
APPL. NO.: 8-138,367
FILED: October 15, 1993 (19931015)

FULL TEXT: 1037 lines

ABSTRACT

Alginate beads are employed as a site specific oral delivery system for cationic therapeutic agents, such as TGF- beta sub 1, designed to target the agents to the luminal side of the small intestine. Improved delivery of bioactive material is obtained by: 1) incorporating selected polyanions in the alginate beads to shield the cationic therapeutic agent from interaction with alginate and/or 2) acid treating alginate beads containing the therapeutic agents to reduce the molecular weight of alginate and its interaction with the agents. Enhanced bioactivity of therapeutic agents released from the alginate is attributed to the ability of polyacrylic acid to shield the agents from interaction with lower molecular fragments of acid treated alginate.

9/3,AB/15 (Item 15 from file: 654)
DIALOG(R)File 654:US PAT.FULL.

02444728
Utility
BIOCOMPATIBLE OCULAR IMPLANTS

PATENT NO.: 5,443,505
ISSUED: August 22, 1995 (19950822)
INVENTOR(s): Wong, Vernon G., Rockville, MD (Maryland), US (United States of America)
Kochinke, Frank, San Jose, CA (California), US (United States of America)
ASSIGNEE(s): Oculex Pharmaceuticals, Inc, (A U.S. Company or Corporation), Palo Alto, CA (California), US (United States of America)
[Assignee Code(s): 41997]
APPL. NO.: 8-153,184
FILED: November 15, 1993 (19931115)

FULL TEXT: 983 lines

ABSTRACT

Implants comprising active agents are employed for introduction into a suprachoroidal space or an avascular region of an eye for therapeutic purposes. The administration of drags is controlled and maintained for long periods of time, while ensuring the substantial absence of significant

levels outside the site of administration.

9/3,AB/16 (Item 16 from file: 654)
DIALOG(R)File 654:US PAT.FULL.

02380671
Utility
CAPSULE WHICH COMPRISES A COMPONENT SUBJECT TO DEGRADATION AND A COMPOSITE POLYMER
[Enzyme-containing detergents; hydrophobic polymer core, hydrophilic water soluble polymer attached to the hydrophobic core]

PATENT NO.: 5,385,959
ISSUED: January 31, 1995 (19950131)
INVENTOR(s): Tsaur, Liang S., Norwood, NJ (New Jersey), US (United States of America)
Aronson, Michael P., West Nyack, NY (New York), US (United States of America)
ASSIGNEE(s): Lever Brothers Company, Division of Conopco, Inc, (A U.S. Company or Corporation), New York, NY (New York), US (United States of America)
[Assignee Code(s): 23809]
APPL. NO.: 8-36,766
FILED: March 25, 1993 (19930325)

This application is a continuation-in-part of 07-875,914 filed Apr. 29, 1992, now abandoned.

FULL TEXT: 1656 lines

ABSTRACT

The present invention relates to a capsule for use in heavy duty liquid compositions which capsule comprises:
(1) a component subject to degradative attack; and
(2) a composite polymer which in turn comprises a hydrophilic portion and hydrophobic polymer core particle.

9/3,AB/17 (Item 17 from file: 654)
DIALOG(R)File 654:US PAT.FULL.

02359434
Utility
GANGLIOSIDES WITH IMMUNOSUPPRESSIVE CERAMIDE MOIETIES
[Autoimmune diseases]

PATENT NO.: 5,366,963
ISSUED: November 22, 1994 (19941122)
INVENTOR(s): Ladisch, Stephan, Chevy Chase, MD (Maryland), US (United States of America)
ASSIGNEE(s): The Regents of the University of California, (A U.S. Company or Corporation), Oakland, CA (California), US (United States of America)
[Assignee Code(s): 13234]
APPL. NO.: 8-21,734
FILED: February 23, 1993 (19930223)

This is a continuation of copending application(s) Ser. No. 07-738,591 filed on Jul. 31, 1991, now abandoned.

FULL TEXT: 844 lines

ABSTRACT

A method for suppressing immune responses in animals by administering a mixture of gangliosides to the animal where the gangliosides have heterogeneous ceramide structures containing fatty acid portions with carbon chain lengths of 21-30 or less than 18 carbon atoms. Ganglioside mixtures which are homogeneous with respect to the fatty acid portion are also effective immunosuppressive agents when the carbon chain length of the fatty acid portion is less than 18. Compositions containing the above specified ganglioside mixtures are also disclosed.

9/3,AB/18 (Item 18 from file: 654)
DIALOG(R)File 654:US PAT.FULL.

02264657

Utility
PROTEASE CONTAINING HEAVY DUTY LIQUID DETERGENT COMPOSITIONS COMPRISING CAPSULES COMPRISING NON-PROTEOLYTIC ENZYME AND COMPOSITE POLYMER
[Anionic, nonionic, cationic, ampholytic, or zwitterion surfactant,proteolytic enzyme, and a composite polymer comprising hydrophobic core particles and hydrophilic water soluble polymer attached to the core]

PATENT NO.: 5,281,357
ISSUED: January 25, 1994 (19940125)
INVENTOR(s): Morgan, Leslie J., Jersey City, NJ (New Jersey), US (United States of America)
Aronson, Michael P., West Nyack, NY (New York), US (United States of America)
Tsaur, Liang S., Norwood, NJ (New Jersey), US (United States of America)
Hessel, John F., Metuchen, NJ (New Jersey), US (United States of America)
McCown, Jack T., Cresskill, NJ (New Jersey), US (United States of America)
ASSIGNEE(s): Lever Brothers Company, Division of Conopco, Inc , (A U.S. Company or Corporation), New York, NY (New York), US (United States of America)
[Assignee Code(s): 23809]
APPL. NO.: 8-37,068
FILED: March 25, 1993 (19930325)

FULL TEXT: 1652 lines

ABSTRACT

The present invention relates to a protease containing heavy duty liquid composition comprising
(a) a capsule which comprises a non-proteolytic enzyme; and
(b) a composite polymer which in turn comprises a hydrophilic portion and hydrophobic polymer core particles.

9/3,AB/19 (Item 19 from file: 654)
DIALOG(R)File 654:US PAT.FULL.

02264656

Utility
HEAVY DUTY LIQUID DETERGENT COMPOSITIONS CONTAINING NON-PROTEOLYTIC ENZYMES

COMPRISING CAPSULES COMPRISING PROTEOLYTIC ENZYME AND COMPOSITE POLYMER [Cores and capsules]

PATENT NO.: 5,281,356
ISSUED: January 25, 1994 (19940125)
INVENTOR(s): Tsaur, Liang S., Norwood, NJ (New Jersey), US (United States of America)
Aronson, Michael P., West Nyack, NY (New York), US (United States of America)
Morgan, Leslie J., Jersey City, NJ (New Jersey), US (United States of America)
Hessel, John F., Metuchen, NJ (New Jersey), US (United States of America)
McCown, Jack T., Cresskill, NJ (New Jersey), US (United States of America)
Gormley, John L., Midland Park, NJ (New Jersey), US (United States of America)
ASSIGNEE(s): Lever Brothers Company, (A U.S. Company or Corporation), New York, NY (New York), US (United States of America)
[Assignee Code(s): 49528]
APPL. NO.: 8-37,053
FILED: March 25, 1993 (19930325)
DISCLAIMER: January 01, 2011 (20110101)

FULL TEXT: 1705 lines

ABSTRACT

The present invention relates to heavy duty liquid compositions containing non-proteolytic enzyme or enzymes and comprising (a) a capsule which comprises a proteolytic enzyme and (b) a composite polymer which in turn comprises a hydrophilic portion and hydrophobic polymer core particles.

9/3,AB/20 (Item 20 from file: 654)
DIALOG(R)File 654:US PAT.FULL.

02264655
Utility
HEAVY DUTY LIQUID DETERGENT COMPOSITIONS CONTAINING A CAPSULE WHICH COMPRISES A COMPONENT SUBJECT TO DEGRADATION AND A COMPOSITE POLYMER [Anionic, nonionic, cationic, ampholytic, or zwitterion surfactant capsules comprising enzymes and a composite polymer comprising hydrophobic core particles and hydrophilic water soluble polymer attached to the core]

PATENT NO.: 5,281,355
ISSUED: January 25, 1994 (19940125)
INVENTOR(s): Tsaur, Liang S., Norwood, NJ (New Jersey), US (United States of America)
Aronson, Michael P., West Nyack, NY (New York), US (United States of America)
Morgan, Leslie J., Jersey City, NJ (New Jersey), US (United States of America)
Hessel, John F., Metuchen, NJ (New Jersey), US (United States of America)
McCown, Jack T., Cresskill, NJ (New Jersey), US (United States of America)
ASSIGNEE(s): Lever Brothers Company, Division of Conopco, Inc , (A U.S. Company or Corporation), New York, NY (New York), US (United States of America)
[Assignee Code(s): 23809]
EXTRA INFO: Assignment transaction [Reassigned], recorded March 21, 1994 (19940321)
APPL. NO.: 8-36,775

FILED: March 25, 1993 (19930325)

RELATED APPLICATIONS

The present application is a continuation-in-part of U.S. Ser. No. 07-875,872 filed Apr. 29, 1992, now abandoned.

FULL TEXT: 1716 lines

ABSTRACT

The present invention relates to a heavy duty liquid compositions comprising (a) a capsule comprising a component subject to degradative attach; and (b) a composite polymer which in turn comprises a hydrophilic portion and hydrophobic polymer core particles.

? t s9/3,ab/21-40

>>>No matching display code(s) found in file(s): 65, 342, 345, 764

9/3,AB/21 (Item 21 from file: 654)
DIALOG(R)File 654:US PAT.FULL.

02132433
Utility
%BIODEGRADABLE% OCULAR IMPLANTS
[Sustained release drug delivery]

PATENT NO.: 5,164,188
ISSUED: November 17, 1992 (19921117)
INVENTOR(s): Wong, Vernon G., Rockville, MD (Maryland), US (United States of America)
ASSIGNEE(s): Visionex, Inc , (A U.S. Company or Corporation), Sunnyvale, CA (California), US (United States of America)
[Assignee Code(s): 21211]
EXTRA INFO: Assignment transaction [Reassigned], recorded January 30, 1995 (19950130)
APPL. NO.: 7-440,344
FILED: November 22, 1989 (19891122)

FULL TEXT: 525 lines

ABSTRACT

Encapsulated agents are employed for introduction into the suprachoroid of an eye for therapeutic purposes. The administration of drugs is controlled and maintained for long periods of time, while ensuring the substantial absence of significant levels outside the site of administration.

9/3,AB/22 (Item 22 from file: 654)
DIALOG(R)File 654:US PAT.FULL.

01911731
Utility
CONTROLLED RELEASE OF MACROMOLECULAR POLYPEPTIDES
[MICRO-SUSPENSION OF WATER SOLUBLE COMPONENTS IN POLYLACTIDE MATRIC]

PATENT NO.: 4,962,091
ISSUED: October 09, 1990 (19901009)
INVENTOR(s): Eppstein, Deborah A., Palo Alto, CA (California), US (United States of America)
Schryver, Brian B., Redwood City, CA (California), US (United States of America)
ASSIGNEE(s): Syntex (U S A) Inc , (A U.S. Company or Corporation), Palo Alto, CA (California), US (United States of America)
[Assignee Code(s): 82370]
APPL. NO.: 6-866,625
FILED: May 23, 1986 (19860523)

FULL TEXT: 1109 lines

ABSTRACT

An active agent delivery system for the controlled administration of macromolecular polypeptides which comprises a micro-suspension of water-soluble components in a polylactide matrix.

9/3,AB/23 (Item 23 from file: 654)
DIALOG(R)File 654:US PAT.FULL.

01865521
Utility
MAMMAL IMMUNIZATION
[INOCULATING WITH MICROENCAPSULATED %ANTIGEN%]

PATENT NO.: 4,919,929
ISSUED: April 24, 1990 (19900424)
INVENTOR(s): Beck, Lee R., Birmingham, AL (Alabama), US (United States of America)
ASSIGNEE(s): Stolle Research & Development Corporation, (A U.S. Company or Corporation), Birmingham, AL (Alabama), US (United States of America)
[Assignee Code(s): 6083]
EXTRA INFO: Assignment transaction [Reassigned], recorded September 21, 1998 (19980921)
APPL. NO.: 6-910,297
FILED: September 17, 1986 (19860917)

This application is a continuation of application Ser. No. 576,001, filed Feb. 1, 1984, now abandoned.

FULL TEXT: 919 lines

ABSTRACT

Mammals are brought to a specific state of immunization by administering an amount of an antigenic substance sufficient to elicit an immunization response to said mammal, said antigenic substance being incorporated within a shaped structure of a biocompatible matrix material.

9/3,AB/24 (Item 1 from file: 653)
DIALOG(R)File 653:US Patents Fulltext

01690222
Utility
ACTIVE/PASSIVE IMMUNIZATION OF THE INTERNAL FEMALE REPRODUCTIVE ORGANS
[Duplicating menstrual cycle of host while administering antibody or %antigen% by depositing estrogen, progestin, antibody or %antigen% containing %microparticles% in vagina]

PATENT NO.: 4,756,907
ISSUED: July 12, 1988 (19880712)
INVENTOR(s): Beck, Lee R., Birmingham, AL (Alabama), US (United States of America)
Flowers, Jr. Charles F., Birmingham, AL (Alabama), US (United States of America)
Cowsar, Donald R., Birmingham, AL (Alabama), US (United States of America)
Tanquary, Albert C., Birmingham, AL (Alabama), US (United States of America)
ASSIGNEE(s): Stolle Research & Development Corp , (A U.S. Company or Corporation), Lebanon, OH (Ohio), US (United States of America)
[Assignee Code(s): 6083]

EXTRA INFO: Assignment transaction [Reassigned], recorded May 6, 1996 (19960506)
Assignment transaction [Reassigned], recorded January 9, 1997 (19970109)
Expired, effective July 12, 2000 (20000712), recorded in O.G. of September 12, 2000 (20000912)
APPL. NO.: 6-822,236
FILED: January 24, 1986 (19860124)

This is a continuation of application Ser. No. 217,746, filed Dec. 18, 1980, now U.S. Pat. No. 4,585,651 which is a continuation of application Ser. No. 952,109 now abandoned, filed Oct. 17, 1978.

FULL TEXT: 1196 lines

ABSTRACT

Antibody or %antigen% containing %microparticles% for the active or passive immunization of the internal female reproductive organs, comprising: %microparticles% of an %antigen% or antibody incorporated in a matrix material which is biocompatible and biologically degradable, said %microparticles% capable of being transported after deposition in the vagina by the natural transport mechanism of the internal female reproductive organs across the cervix into the uterus.

9/3,AB/25 (Item 2 from file: 653)
DIALOG(R)File 653:US Patents Fulltext

01664056

Utility
ACTIVE/PASSIVE IMMUNIZATION OF THE INTERNAL FEMALE REPRODUCTIVE ORGANS [ANTIGENS, ANTIBODIES, IMMUNIZATION]

PATENT NO.: 4,732,763
ISSUED: March 22, 1988 (19880322)
INVENTOR(s): Beck, Lee R., Birmingham, AL (Alabama), US (United States of America)
Flowers, Charles F., Birmingham, AL (Alabama), US (United States of America)
Cowsar, Donald R., Birmingham, AL (Alabama), US (United States of America)
Tanquary, Albert C., Birmingham, AL (Alabama), US (United States of America)
ASSIGNEE(s): Stolle Research and Development Corporation, (A U.S. Company or Corporation), Cincinnati, OH (Ohio), US (United States of America)
[Assignee Code(s): 6083]
EXTRA INFO: Assignment transaction [Reassigned], recorded May 6, 1996 (19960506)
Assignment transaction [Reassigned], recorded January 9, 1997 (19970109)
Expired, effective March 22, 2000 (20000322), recorded in O.G. of May 30, 2000 (20000530)
APPL. NO.: 6-655,989
FILED: September 28, 1984 (19840928)

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of application Ser. No. 121,480, filed Feb. 14, 1980 which in turn is a continuation-in-part of application Ser. No. 952,109, filed Oct. 17, 1978, now both abandoned.

FULL TEXT: 1200 lines

ABSTRACT

Antibody or %antigen% containing %microparticles% for the active or passive immunization of the internal female reproductive organs, comprising: %microparticles% of an %antigen% or antibody incorporated in a matrix material which is biocompatible and biologically degradable, said %microparticles% capable of being transported after deposition in the vagina by the natural transport mechanism of the internal female reproductive organs across the cervix into the uterus.

9/3,AB/26 (Item 3 from file: 653)
DIALOG(R)File 653:US Patents Fulltext

01504608

Utility
ACTIVE/PASSIVE IMMUNIZATION OF THE INTERNAL FEMALE REPRODUCTIVE ORGANS [ANTIFERTILITY VACCINE]

PATENT NO.: 4,585,651
ISSUED: April 29, 1986 (19860429)
INVENTOR(s): Beck, Lee R., Birmingham, AL (Alabama), US (United States of America)
Flowers, Jr. Charles F., Birmingham, AL (Alabama), US (United States of America)
Cowsar, Donald R., Birmingham, AL (Alabama), US (United States of America)
Tanquary, Albert C., Birmingham, AL (Alabama), US (United States of America)
ASSIGNEE(s): Stolle Research & Development Corporation, (A U.S. Company or Corporation), Lebanon, OH (Ohio), US (United States of America)
[Assignee Code(s): 6083]
EXTRA INFO: Assignment transaction [Reassigned], recorded May 6, 1996 (19960506)
Assignment transaction [Reassigned], recorded January 9, 1997 (19970109)
Expired, effective April 29, 1998 (19980429), recorded in O.G. of July 7, 1998 (19980707)
APPL. NO.: 6-217,746
FILED: December 18, 1980 (19801218)

This is a continuation of application Ser. No. 952,109, filed Oct. 17, 1978, now abandoned.

FULL TEXT: 964 lines

ABSTRACT

Antibody or %antigen% containing %microparticles% for the active or passive immunization of the internal female reproductive organs, comprising: %microparticles% of an %antigen% or antibody incorporated in a matrix material which is biocompatible and biologically degradable, said %microparticles% capable of being transported after deposition in the vagina by the natural transport mechanism of the internal female reproductive organs across the cervix into the uterus.

9/3,AB/27 (Item 4 from file: 653)
DIALOG(R)File 653:US Patents Fulltext

01358530

Utility
%BIODEGRADABLE%, IMPLANTABLE DRUG DELIVERY DEPOTS, AND METHOD FOR PREPARING AND USING THE SAME
[MATRICES OF A POLYLACTAM COPOLYMER OF GLUTAMIC ACID AND MONOETHYL GLUTAMATE; CONTROLLED AND SUSTAINED RELEASE]

PATENT NO.: 4,450,150
ISSUED: May 22, 1984 (19840522)
INVENTOR(s): Sidman, Kenneth R., Wayland, MA (Massachusettes), US (United States of America)
ASSIGNEE(s): Arthur D Little, Inc , (A U.S. Company or Corporation), Cambridge, MA (Massachusettes), US (United States of America) [Assignee Code(s): 50200]
EXTRA INFO: Expired, effective May 22, 1996 (19960522), recorded in O.G. of July 30, 1996 (19960730)
APPL. NO.: 6-262,149
FILED: May 11, 1981 (19810511)
PRIORITY: 199552, CA (Canada), May 10, 1974 (19740510)
6744-74, CH (Switzerland), May 16, 1974 (19740516)
2424169, DE (Germany), May 17, 1974 (19740517)
74-34307, FR (France), November 10, 1974 (19741110)
21361-74, GB (United Kingdom), May 14, 1974 (19740514)
48-54595, JP (Japan), May 17, 1974 (19740517)

This application is a continuation-in-part of my application Ser. No. 896,552 filed Apr. 14, 1978 now abandoned, which was filed as a continuation-in-part of my application Ser. No. 596,444 filed July 16, 1975, which in turn is a continuation-in-part of my application Ser. No. 361,182 filed May 17, 1973, and now abandoned.

FULL TEXT: 1081 lines

ABSTRACT

An implantable drug deliver depot comprising a hydrophilic poly(glutamic acid-co-ethyl glutamate) structure having one or more substances, e.g., drugs and/or diagnostic agents physically contained therein. The drug or diagnostic agent is released by its permeation of and diffusion through the copolymer structure. The depot may be designed to release the substance or substances at predetermined rates and in predetermined sequence. The copolymer structure ultimately biodegrades to glutamic acid. Among the preferred configurations for the depots are rods and closed-end capsules.

9/3,AB/28 (Item 1 from file: 349)
DIALOG(R)File 349:PCT Fulltext

00606160
< i> ENTEROCOCCUS FAECALIS < /i> POLYNUCLEOTIDES AND POLYPEPTIDES
POLYNUCLEOTIDES ET POLYPEPTIDES D'< i> ENTEROCOCCUS FAECALIS < /i>
Patent Applicant/Assignee:
HUMAN GENOME SCIENCES INC, HUMAN GENOME SCIENCES, INC. , 9410 Key West Avenue, Rockville, MD 20850 , US
Inventor(s):
KUNSCH Charles A, KUNSCH, Charles, A. , 4083 Spalding Hollow, Norcross, GA 30092 , US
DILLON Patrick J, DILLON, Patrick, J. , 1055 Snipe Court, Carlsbad, CA 92009 , US
BARASH Steven C, BARASH, Steven, C. , 582 College Parkway &303, Rockville, MD 20850 , US
Patent and Priority Information (Country, Number, Date):
Patent: WO 9850555 A2 19981112

Application: WO 98US8985 19980504 (PCT/WO US9808985)
Priority Application: US 9744031 19970506; US 9746655 19970516; US 9766009 19971114
Designated States: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG
Publication Language: English
Filing Language: English
Fulltext Word Count: 491623

English Abstract
The present invention provides polynucleotide sequences of the genome of < i> Enterococcus faecalis < /i> , polypeptide sequences encoded by the polynucleotide sequences, corresponding polynucleotides and polypeptides, vectors and hosts comprising the polynucleotides, and assays and other uses thereof. The present invention further provides polynucleotide and polypeptide sequence information stored on computer readable media, and computer-based systems and methods which facilitate its use.

French Abstract
Cette invention, qui a trait a des sequences polynucleotidiques du genome d'< i> Enterococcus faecalis < /i> , a des sequences polypeptidiques codees par les sequences polynucleotidiques, aux polynucleotides et polypeptides correspondants, ainsi qu'a des vecteurs et a des hotes comportant les polynucleotides, porte egalement sur des epreuves les concernant et d'autres utilisations qui en sont faites. Elle concerne, de surcroit, une information relative aux sequences polynucleotidiques et polypeptidiques stockees sur des supports informatiques ainsi que des systemes et des methodes informatiques facilitant leur utilisation.

9/3,AB/29 (Item 2 from file: 349)
DIALOG(R)File 349:PCT Fulltext

00605754
NOVEL PRODRUGS COMPRISING FLUORINATED AMPHIPHILES
NOUVEAUX PROMEDICAMENTS RENFERMANT DES AMPHIPHILES FLUORES
Patent Applicant/Assignee:
IMARX PHARMACEUTICAL CORP, IMARX PHARMACEUTICAL CORP. , 1635 East 18th Street, Tucson, AZ 85749 , US
Inventor(s):
UNGER Evan C, UNGER, Evan, C. , 13365 East Camino La Cebadilla, Tucson, AZ 85749 , US
Patent and Priority Information (Country, Number, Date):
Patent: WO 9850041 A1 19981112
Application: WO 98US7712 19980415 (PCT/WO US9807712)
Priority Application: US 97851780 19970506; US 97887215 19970702
Designated States: AU BR CA JP AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
Publication Language: English
Filing Language: English
Fulltext Word Count: 56382

English Abstract
The present invention describes, < i> inter alia < /i> , novel prodrugs comprising fluorinated amphiphiles, compositions comprising the novel prodrugs, and methods of use of the prodrugs and compositions.

French Abstract
La presente invention concerne, entre autres, de nouveaux promedicaments renfermant des amphiphiles, des compositions contenant ces nouveaux promedicaments, ainsi que des procedes d'utilisation de ces

promedicaments et de ces compositions.

9/3,AB/30 (Item 3 from file: 349)
DIALOG(R)File 349:PCT Fulltext

00605753
NOVEL LIPID SOLUBLE STEROID PRODRUGS
NOUVEAUX PROMEDICAMENTS STEROIDES LIPOSOLUBLES
Patent Applicant/Assignee:
IMARX PHARMACEUTICAL CORP, IMARX PHARMACEUTICAL CORP. , 1635 East 18th Street, Tucson, AZ 85749 , US
Inventor(s):
UNGER Evan C, UNGER, Evan, C. , 13365 East Camino La Cebadilla, Tucson, AZ 85749 , US
SHEN DeKang, SHEN, DeKang , 2602 W. Aiden Street, Tucson, AZ 85745 , US
Patent and Priority Information (Country, Number, Date):
Patent: WO 9850040 A1 19981112
Application: WO 98US7492 19980415 (PCT/WO US9807492)
Priority Application: US 97851780 19970506
Designated States: AU BR CA JP AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
Publication Language: English
Filing Language: English
Fulltext Word Count: 55680

English Abstract
The present invention is directed to novel lipid soluble steroid prodrugs, compositions comprising steroid prodrugs, and uses of the same.

French Abstract
La presente invention concerne de nouveaux promedicaments steroides liposolubles, des compositions renfermant des promedicaments steroides, ainsi que leur utilisation.

9/3,AB/31 (Item 4 from file: 349)
DIALOG(R)File 349:PCT Fulltext

00604065
PEPTIDES WHICH ENHANCE TRANSPORT OF AN ACTIVE AGENT ACROSS TISSUES AND COMPOSITIONS AND METHODS OF USING THE SAME
PEPTIDES FAVORISANT LE TRANSPORT D'UN AGENT ACTIF DANS LES TISSUS, COMPOSITIONS LES RENFERMANT ET LEURS PROCEDES D'UTILISATION
Patent Applicant/Assignee:
ELAN CORPORATION PLC, ELAN CORPORATION, PLC , Lincoln House, Lincoln Place, Dublin 2 , IE
CYTOGEN CORPORATION, CYTOGEN CORPORATION , 600 College Road East CN-5308, Princeton, NJ 08540-5308 , US
Inventor(s):
O'MAHONY Daniel Joseph, O'MAHONY, Daniel, Joseph , 75 Avoca Park, Avoca Avenue, Blackrock, County Dublin , IE
ALVAREZ Vernon Leon, ALVAREZ, Vernon, Leon , 187 Rice Drive, Morrisville, PA 19067 , US
SEVESO Michela, SEVESO, Michela , Apartment 89, Marlborough Court, Marlborough Street, Dublin 1 , IE
Patent and Priority Information (Country, Number, Date):
Patent: WO 9851825 A1 19981119
Application: WO 98US10079 19980515 (PCT/WO US9810079)
Priority Application: US 97857046 19970515
Designated States: AL AU BB BG BR CA CN CU EE GE HU IL IS JP KP KR LK LT LV MK MX NO NZ PL RO RU SG SI SK TR TT UA US VN GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

Publication Language: English
Filing Language: English
Fulltext Word Count: 21941

English Abstract
Targeting agents that are capable of permitting or facilitating transport of an active agent through a human or animal gastro-intestinal tissue. These targeting agents are peptides or their derivatives (e.g., fragments) and peptidomimetics thereof, and the nucleotide sequences coding for the peptides and derivatives. The targeting agents have use in facilitating transport of active agents from the lumenal side of the GIT into the systemic blood system, and/or in targeting active agents to the GIT. Therapeutic methods of administration, pharmaceutical compositions and formulations based on the targeting agent peptides are also provided. Preferably, the active agent is a drug or drug-containing nano- or %microparticle%.

French Abstract
L'invention concerne des agents de ciblage permettant ou facilitant le transport d'un agent actif dans des tissus gastro- intestinaux humains ou animaux. Ces agents de ciblage sont des peptides, ou leurs derives (par exemple des fragments) et leur peptidomimetique, ainsi que les sequences codant ces peptides et leurs derives. L'utilisation de ces agents de ciblage facilite le transport d'agents actifs de la lumiere du tractus gastro-intestinal a l'ensemble du systeme cardio-vasculaire, et/ou cible lesdits agents actifs vers ledit tractus gastro-intestinal. L'invention concerne egalement des procedes d'administration therapeutiques ainsi que des compositions et des formulations pharmaceutiques a base des peptides agents de ciblage. L'agent actif est de preference un medicament, ou une microparticule ou une nanoparticule renfermant un medicament.

9/3,AB/32 (Item 5 from file: 349)
DIALOG(R)File 349:PCT Fulltext

00603717
RANDOM PEPTIDES THAT BIND TO GASTRO-INTESTINAL TRACT (GIT) TRANSPORT RECEPTORS AND RELATED METHODS
PEPTIDES ALEATOIRES SE LIANT AU RECEPTEURS DE TRANSPORT DU TRACTUS GASTROINTESTINAL (GIT) ET PROCEDES Y RELATIFS
Patent Applicant/Assignee:
CYTOGEN CORPORATION, CYTOGEN CORPORATION , 600 College Road East, Princeton, NJ 08540 , US
ELAN CORPORATION PLC, ELAN CORPORATION, PLC , Lincoln House, Lincoln Place, Dublin 2 , IE
Inventor(s):
ALVAREZ Vernon L, ALVAREZ, Vernon, L. , 187 Rice Drive, Morrisville, PA 19067 , US
O'MAHONY Daniel J, O'MAHONY, Daniel, J. , 75 Avoca Park, Avoca Avenue, Blackrock, Dublin , IE
LAMBKIN Imelda J, LAMBKIN, Imelda, J. , 9 Station Road, Sutton, Dublin 13 , IE
PATTERSON Catherine A, PATTERSON, Catherine, A. , 3 Grange Crescent, Pottery Road, Dunlaoghaire, Dublin , IE
SINGLETON Judith, SINGLETON, Judith , Knoll Way, Rocky Way, NJ 08553 , US
BELINKA Benjamin A Jr, BELINKA, Benjamin, A., Jr. , 15 Pelham Road, Kendall Park, NJ 08824 , US
CARTER John M, CARTER, John, M. , 35 Chicory Lane, Trenton, NJ 08638-1926 , US
CAGNEY Gerard M, CAGNEY, Gerard, M. , 2618 Yale Avenue East, Seattle, WA 98102 , US
Patent and Priority Information (Country, Number, Date):
Patent: WO 9851325 A2 19981119
Application: WO 98US10088 19980515 (PCT/WO US9810088)
Priority Application: US 9746595 19970515

Designated States: AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE GH GW HU ID IL IS JP KG KP KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG
Publication Language: English
Filing Language: English
Fulltext Word Count: 72056

English Abstract
This invention relates to proteins (e.g., peptides) that are capable of facilitating transport of an active agent through a human or animal gastro-intestinal tissue, and derivatives (e.g., fragments) and analogs thereof, and nucleotide sequences coding for said proteins and derivatives. The proteins of the invention have use in facilitating transport of active agents from the lumenal side of the GIT into the systemic blood system, and/or in targeting active agents to the GIT. Thus, for example, by binding (covalently or noncovalently) a protein of the invention to an orally administered drug, the drug can be targeted to specific receptor sites or transport pathways which are known to operate in the human gastro-intestinal tract, thus facilitating its absorption into the systemic system.

French Abstract
L'invention concerne des proteines (par exemple des peptides) capable de faciliter le transport d'un agent actif a travers les tissus gastro-intestinaux d'un humain ou d'un animal. L'invention concerne egalement des derives (par exemple des fragments) et des analogues de ces proteines, ainsi que des sequences nucleotidiques codant ces proteines et ces derives. Les proteines de cette invention sont utiles pour faciliter le transport d'agents actifs depuis le cote lumiere desdits tissus gastro-intestinaux, jusque dans l'appareil cardiovasculaire systemique, et/ou pour diriger des agents actifs vers ces tissus. Ainsi, par exemple, grace a la liaison (par covalence ou non) d'une proteine de cette invention a un medicament administre par voie orale, ce medicament peut etre dirige vers des sites recepteurs specifiques ou des voies de transport connues pour fonctionner dans le tractus gastrointestinal humain, facilitant ainsi son absorption dans le systeme systemique.

9/3,AB/33 (Item 6 from file: 349)
DIALOG(R)File 349:PCT Fulltext

00598423
DIAGNOSIS AND PROGNOSIS OF GLAUCOMA
DIAGNOSTIC ET PRONOSTIC DU GLAUCOME
Patent Applicant/Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA , Suite 150, 1320 Harbor Bay Parkway, Alameda, CA 94502 , US
Inventor(s):
NGUYEN Thai D, NGUYEN, Thai, D. , 17 Central Drive, Mill Valley, CA 94941 , US
POLANSKY Jon R, POLANSKY, Jon, R. , 15 Stanton Way, Mill Valley, CA 94941 , US
HUANG Weidong, HUANG, Weidong , 42 Behr Avenue, San Francisco, CA 94131 , US
Patent and Priority Information (Country, Number, Date):
Patent: WO 9844108 A1 19981008
Application: WO 97US5801 19970407 (PCT/WO US9705801)
Priority Application: WO 97US5391 19970401
Designated States: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU GH KE LS MW SD SZ UG AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR

IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG
Publication Language: English
Filing Language: English
Fulltext Word Count: 13867

English Abstract
A glucocorticoid-induced protein, TIGR*, that is produced by cells of the trabecular meshwork can be used to diagnose glaucoma. The TIGR* protein, anti-TIGR* antibodies, and TIGR* encoding sequences also provide a diagnostic for glaucoma and its related diseases.

French Abstract
L'invention se rapporte a une proteine induite par glucocorticoides, proteine TIGR* (reponse glucocorticoidique induite par le reseau trabeculaire), qui est produite par des cellules du reseau trabeculaire et qui peut etre utilisee pour diagnostiquer le glaucome. La proteine TIGR*, les anticorps anti-TIGR* et les sequences codant TIGR* assurent egalement le diagnostic du glaucome et des maladies qui y sont associees.

9/3,AB/34 (Item 7 from file: 349)
DIALOG(R)File 349:PCT Fulltext

00598422
DIAGNOSIS AND PROGNOSIS OF GLAUCOMA
DIAGNOSTIC ET PRONOSTIC DU GLAUCOME
Patent Applicant/Assignee:
THE REGENTS OF THE UNIVERISITY OF CALIFORNIA, THE REGENTS OF THE UNIVERISITY OF CALIFORNIA , Suite 150, 1320 Harbor Bay Parkway, Alameda, CA 94502 , US
Inventor(s):
NGUYEN Thai D, NGUYEN, Thai, D. , 17 Central Drive, Mill Valley, CA 94941 , US
POLANSKY Jon R, POLANSKY, Jon, R. , 15 Stanton Way, Mill Valley, CA 94941 , US
HUANG Weidong, HUANG, Weidong , 42 Behr Avenue, San Francisco, CA 94131 , US
Patent and Priority Information (Country, Number, Date):
Patent: WO 9844107 A1 19981008
Application: WO 97US5391 19970401 (PCT/WO US9705391)
Priority Application: WO 97US5391 19970401
Designated States: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU GH KE LS MW SD SZ UG AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG
Publication Language: English
Filing Language: English
Fulltext Word Count: 13898

English Abstract
A glucocorticoid-induced protein, TIGR*, that is produced by cells of the trabecular meshwork can be used to diagnose glaucoma. The TIGR* protein, anti-TIGR* antibodies, and TIGR* encoding sequences also provide a diagnostic for glaucoma and its related diseases.

French Abstract
L'invention se rapporte a une proteine induite par glucocorticoides, proteine TIGR* (reponse glucocorticoidique induite par le reseau trabeculaire), qui est produite par des cellules du reseau trabeculaire et qui peut etre utilisee pour diagnostiquer le glaucome. La proteine TIGR*, les anticorps anti-TIGR* et les sequences codant TIGR* assurent egalement le diagnostic du glaucome et des maladies qui y sont associees.

9/3,AB/35 (Item 8 from file: 349)
DIALOG(R)File 349:PCT Fulltext

00589031
USE OF %MICROPARTICLES% WITH ADSORBED %ANTIGEN% TO STIMULATE IMMUNE RESPONSES
UTILISATION DE MICROPARTICULES CONTENANT UN ANTIGENE ADSORBE DANS LE BUT DE STIMULER LES REPONSES IMMUNITAIRES
Patent Applicant/Assignee:
CHIRON CORPORATION, CHIRON CORPORATION , 4560 Horton Street, Emeryville, CA 94608 , US
Inventor(s):
O'HAGAN Derek, O'HAGAN, Derek , Chiron Corporation, 4560 Horton Street, R-440, Emeryville, CA 94608 , US
VAN NEST Gary, VAN NEST, Gary , Chiron Corporation, 4560 Horton Street, R-440, Emeryville, CA 94608 , US
OTT Gary S, OTT, Gary, S. , Chiron Corporation, 4560 Horton Street, R-440, Emeryville, CA 94608 , US
BARACKMAN John, BARACKMAN, John , Chiron Corporation, 4560 Horton Street, R-440, Emeryville, CA 94608 , US
KAZZAZ Jina, KAZZAZ, Jina , Chiron Corporation, 4560 Horton Street, R-440, Emeryville, CA 94608 , US
Patent and Priority Information (Country, Number, Date):
Patent: WO 9833487 A1 19980806
Application: WO 98US1738 19980129 (PCT/WO US9801738)
Priority Application: US 9736316 19970130; US 9769749 19971216
Designated States: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG
Publication Language: English
Filing Language: English
Fulltext Word Count: 8601

English Abstract
The use of poly(lactide) or poly(lactide-co-glycolide) %microparticles% with adsorbed %antigen% is disclosed. The %microparticles% are useful for enhancing CTL responses to a selected %antigen%.

French Abstract
La presente invention concerne l'utilisation de microparticules de polylactide ou de polylactide-co-glycolide contenant un antigene adsorbe. Ces microparticules sont utilisees pour stimuler la reponse des cellules T cytotoxiques envers un antigene selectionne.

9/3,AB/36 (Item 9 from file: 349)
DIALOG(R)File 349:PCT Fulltext

00589022
RNA- AND DNA-BASED ACTIVE AGENTS IN NANOPARTICLES
AGENTS ACTIFS A BASE D'ARN ET D'ADN DANS DES NANOPARTICULES
Patent Applicant/Assignee:
GURNY Robert, GURNY, Robert , Universite de Geneve, 30, quai Ernest Ansermet, CH-1211 Geneve , CH
Inventor(s):
GURNY Robert, GURNY, Robert , Universite de Geneve, 30, quai Ernest Ansermet, CH-1211 Geneve , CH
Patent and Priority Information (Country, Number, Date):
Patent: WO 9833478 A2 19980806
Application: WO 98EP420 19980126 (PCT/WO EP9800420)
Priority Application: EP 97101450 19970130

Designated States: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG
Publication Language: English
Filing Language: English
Fulltext Word Count: 7832

English Abstract
The invention relates to a pharmaceutical composition which is suitable for the incorporation of RNA- and DNA-based active agents in nanoparticles, which are efficient as drug carriers. The active agents may be oligonucleotides or so-called "smart biological bombs". The composition is characterized by the following components: a) the active agent to be incorporated in combination with cationic surfactants within nanoparticles by dispersion methods; b) a pharmaceutically acceptable %biodegradable% synthetic polymer which is suitable for the formation of nanoparticles; c) and, optionally, further pharmaceutically acceptable additives.

French Abstract
L'invention concerne une composition pharmaceutique qui peut etre incorporee dans des agents actifs a base d'ARN et d'ADN, dans des nanoparticules, qui constituent des vecteurs de medicaments efficaces. Ces agents actifs peuvent etre des oligonucleotides ou des agents dits "bombes biologiques intelligentes". Cette composition se caracterise par les composants suivants: (a) l'agent actif est incorpore en combinaison avec des tensioactifs cationiques dans des nanoparticules par des procedes de dispersion: (b) un polymere de synthese %biodegradable% pharmaceutiquement acceptable qui convient pour la formation de nanoparticules; et (c) eventuellement, d'autres additifs pharmaceutiquement acceptables.

9/3,AB/37 (Item 10 from file: 349)
DIALOG(R)File 349:PCT Fulltext

00588278
METHODS FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF GLAUCOMA AND RELATED DISORDERS
PROCEDES DE DIAGNOSTIC, DE PRONOSTIC ET DE TRAITEMENT DU GLAUCOME ET DE TROUBLES ASSOCIES
Patent Applicant/Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, 22nd floor, 300 Lakeside Drive, Oakland, CA 94612-3550, US
Inventor(s):
NGUYEN Thai D, NGUYEN, Thai, D., 17 Central Drive, Mill Valley, CA 94941, US
POLANSKY Jon R, POLANSKY, Jon, R., 15 Stanton Way, Mill Valley, CA 94941, US
CHEN Pu, CHEN, Pu, 6090 Darleen Court, Rohnert Park, CA 94928, US
CHEN Hua, CHEN, Hua, 371 Twentieth Street, San Francisco, CA 94121, US
Patent and Priority Information (Country, Number, Date):
Patent: WO 9832850 A1 19980730
Application: WO 98US468 19980109 (PCT/WO US9800468)
Priority Application: US 97791154 19970128
Designated States: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

Publication Language: English
Filing Language: English
Fulltext Word Count: 31005

English Abstract
The nucleic acid upstream of the TIGR protein encoding sequence can be used to diagnose glaucoma. Polymorphisms, base substitutions, base additions located with the upstream and within TIGR exons can also be used to diagnose glaucoma. In addition, polymorphisms, base substitutions, base additions located with the upstream and within TIGR exons can also be used to prognose glaucoma.

French Abstract
On peut utiliser l'acide nucleique situe en amont de la sequence codant la proteine TIGR afin de diagnostiquer le glaucome. On peut egalement utiliser des polymorphismes, des substitutions de bases, des additions de bases situees au moyen des exons amont et a l'interieur des exons TIGR afin de diagnostiquer le glaucome. De plus, on peut egalement utiliser des polymorphismes, des substitutions de bases, des additions de bases situees au moyen des exons amont et a l'interieur des exons TIGR afin de pronostiquer le glaucome.

9/3,AB/38 (Item 11 from file: 349)
DIALOG(R)File 349:PCT Fulltext

00587014
THERAPEUTIC TREATMENT AND PREVENTION OF INFECTIONS WITH A BIOACTIVE MATERIAL ENCAPSULATED WITHIN A %BIODEGRADABLE%-BIOCOMPATIBLE POLYMERIC MATRIX
TRAITEMENT THERAPEUTIQUE ET PREVENTION D'INFECTIONS A L'AIDE DE SUBSTANCES BIOACTIVES ENCAPSULEES DANS UNE MATRICE POLYMERE %BIODEGRADABLE% -BIOCOMPATIBLE

Patent Applicant/Assignee:
UNITED STATES GOVERNMENT as represented by THE SECRETARY OF THE ARMY, UNITED STATES GOVERNMENT as represented by THE SECRETARY OF THE ARMY , Intellectual Property Law Division, OTJAG, DA, Suite 713, 901 North Stuart Street, Arlington, VA 22203-1837 , US

Inventor(s):
SETTERSTROM Jean A, SETTERSTROM, Jean, A. , 700 Hampton Trace Lane, Alpharetta, GA 30201 , US
VAN HAMONT John E, VAN HAMONT, John, E. , 160A Gardiner Loop, West Point, NY 10996 , US
REID Robert H, REID, Robert, H. , 10807 McComas Court, Kensington, MD 20895 , US
JACOB Elliot, JACOB, Elliot , 11529 Dafford Lane, Silver Spring, MD 20902 , US
JEYANTHI Ramasubbu, JEYANTHI, Ramasubbu , 9725 Clocktower Lane &301, Columbia, MD 21046 , US
BOEDEKER Edgar C, BOEDEKER, Edgar, C. , 7505 Bybrook Lane, Chevy Chase, MD 20815 , US
MCQUEEN Charles E, MCQUEEN, Charles, E. , 16805 Ethelwood Terrace, Olney, MD 20832 , US
TICE Thomas R, TICE, Thomas, R. , 1915 Forest River Court, Birmington, AL 35244 , US
ROBERTS F Donald, ROBERTS, F., Donald , 2 Bridge Path Circle, Dover, MA 02030 , US
FRIDEN Phil, FRIDEN, Phil , 32 Washington Street, Bedford, MA 01730 , US

Patent and Priority Information (Country, Number, Date):
Patent: WO 9832427 A1 19980730
Application: WO 98US1556 19980127 (PCT/WO US9801556)
Priority Application: US 97789734 19970127
Designated States: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU

ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG
Publication Language: English
Filing Language: English
Fulltext Word Count: 63830

English Abstract
Novel burst-free, sustained release biocompatible and %biodegradable% %microcapsules% which can be programmed to release their active core for variable durations ranging from 1-100 days in an aqueous physiological environment. The %microcapsules% are comprised of a core of polypeptide or other biologically active agent encapsulated in a matrix of poly(lactide/glycolide) copolymer, which may contain a pharmaceutically acceptable adjuvant, as a blend of upcapped free carboxyl end group and end-capped forms ranging in ratios from 100/0 to 1/99.

French Abstract
Cette invention se rapporte a de nouvelles %microcapsules% biocompatibles et biodegradables a liberation prolongee, sans pic, qui peuvent etre programmees pour liberer leur noyau actif pour des durees variables allant de 1 a 100 jours dans un milieu physiologique aqueux. Ces %microcapsules% sont constituees par un noyau de polypeptides ou d'un autre agent biologiquement actif encapsule dans une matrice de copolymeres de poly(lactide/glycolide), qui peut contenir un adjuvant acceptable sur le plan pharmaceutique, se presentant sous la forme d'un melange de groupes terminaux a carboxyle libre sans coiffe et de formes a coiffe terminale selon des rapports compris entre 100/0 et 1/99.

9/3,AB/39 (Item 12 from file: 349)
DIALOG(R)File 349:PCT Fulltext

00583915
METHOD OF PRODUCING A SUSTAINED-RELEASE PREPARATION
PROCEDE DE PRODUCTION D'UNE PREPARATION A LIBERATION PROLONGEE
Patent Applicant/Assignee:
TAKEDA CHEMICAL INDUSTRIES LTD, TAKEDA CHEMICAL INDUSTRIES, LTD. , 1-1, Doshomachi 4-chome, Chuo- ku, Osaka-shi, Osaka 541 , JP
Inventor(s):
YAMAGATA Yutaka, YAMAGATA, Yutaka , 1-8-207, Doshodai 1-chome, Suma-ku, Kobe-shi, Hyogo 654 , JP
MISAKI Masafumi, MISAKI, Masafumi , 4-41-103, Hibarigaoka 2-chome, Takarazuka-shi, Hyogo 665 , JP
IWASA Susumu, IWASA, Susumu , 21-2, Ohsumigaoka 1-chome, Kyotanabe-shi, Kyoto 610-03 , JP
Patent and Priority Information (Country, Number, Date):
Patent: WO 9827980 A2 19980702
Application: WO 97JP4671 19971218 (PCT/WO JP9704671)
Priority Application: JP 96342046 19961220
Designated States: AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE GW HU ID IL IS KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG
Publication Language: English
Filing Language: English
Fulltext Word Count: 9834

English Abstract
A method of producing sustained-release %microcapsules% which comprises dispersing a physiologically active polypeptide into a solution of a %biodegradable% polymer and zinc oxide in an organic solvent, followed by removing the organic solvent; which provides a sustained- release preparation showing a high entrapment ratio of the physiologically active

groupe II (tel que CaCl< sub> 2 < /sub>) pour former une suspension de microspheres de polyphosphazene. Les microspheres de polyphosphazene sont ensuite recuperees de la suspension. Ce procede permet d'obtenir des rendements eleves de production de microspheres dont la repartition des dimensions est controlee.

t s9/3,ab/41-65

>>>No matching display code(s) found in file(s): 65, 342, 345, 764

9/3,AB/41 (Item 14 from file: 349)
DIALOG(R)File 349:PCT Fulltext

00542385
ADMINISTRATION OF HISTAMINE FOR THERAPEUTIC PURPOSES
ADMINISTRATION D'HISTAMINE A DES FINS THERAPEUTIQUES
Patent Applicant/Assignee:
MAXIM PHARMACEUTICALS INC, MAXIM PHARMACEUTICALS, INC. , 3099 Science Park Road, San Diego, CA 92121 , US
Inventor(s):
HELLSTRAND Kristoffer, HELLSTRAND, Kristoffer , Brodragatan 19, S412 74 Goteborg , SE
HERMODSSON Svante, HERMODSSON, Svante , Bergsbogatan 2, S431 38 Molndal , SE
Patent and Priority Information (Country, Number, Date):
Patent: WO 9742968 A2 19971120
Application: WO 97US8001 19970512 (PCT/WO US9708001)
Priority Application: US 96649121 19960514; US 96767338 19961216
Designated States: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN YU GH KE LS MW SD SZ UG AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG
Publication Language: English
Filing Language: English
Fulltext Word Count: 9998

English Abstract
Methods for obtaining beneficial stable levels of circulating histamine are disclosed for use in methods for enhancing the cytotoxicity of cytotoxic effector cells. In such methods, a beneficial level of circulating histamine is attained and an agent whose ability to enhance natural killer cell cytotoxicity is augmented by histamine is administered. Alternatively, stable beneficial levels of circulating histamine can be attained in subjects receiving chemotherapy or antiviral treatment. The invention may also be employed in treatments combining histamine, agents which enhance the cytotoxicity of cytotoxic effector cells, and chemotherapeutic agents. Optimization of the delivery of histamine and substances which induce the release of endogenous histamine are also disclosed.

French Abstract
L'invention a trait a des procedes, permettant d'obtenir des taux stables bienfaisants d'histamine circulante, utilisables dans des techniques de renforcement de la cytotoxicite de cellules effectrices cytotoxiques. On obtient, au titre de ces procedes, un taux bienfaisant d'histamine circulante, et l'on administre un agent dont l'aptitude a renforcer la cytotoxicite naturelle d'une cellule lytique est accrue par l'histamine. Dans une variante, on obtient, chez des sujets soignes par chimiotherapie ou suivant un traitement antiviral, des taux stables bienfaisants d'histamine circulante. Cette invention peut egalement servir dans le cas de traitement combinant l'histamine, des agents renforcant la cytotoxicite de cellules effectrices cytotoxiques ainsi que des agents entrant dans une chimiotherapie. L'invention porte egalement sur l'optimalisation de l'administration d'histamine et de substances

provoquant la liberation d'histamine endogene.

9/3,AB/42 (Item 15 from file: 349)
DIALOG(R)File 349:PCT Fulltext

00535523
SUSTAINEDRELEASE PREPARATION AND ITS PRODUCTION
PREPARATION A LIBERATION PROLONGEE ET PRODUCTION DE CETTE PREPARATION
Patent Applicant/Assignee:
TAKEDA CHEMICAL INDUSTRIES LTD, TAKEDA CHEMICAL INDUSTRIES, LTD. , 11, Doshomachi 4chome, Chuoku, Osakashi, Osaka 541 , JP
Inventor(s):
TAKADA Shigeyuki, TAKADA, Shigeyuki , 81319, Ohwakidai, Kitaku, Kobeshi, Hyogo 65111 , JP
KUROKAWA Tomofumi, KUROKAWA, Tomofumi , 50A508, Wakaba 2chome, Inagawacho, Kawabegun, Hyogo 66602 , JP
IWASA Susumu, IWASA, Susumu , 212, Ohsumigaoka 1chome, Tanabecho, Tsuzukigun, Kyoto 61003 , JP
Patent and Priority Information (Country, Number, Date):
Patent: WO 9735563 A2 19971002
Application: WO 97JP1041 19970327 (PCT/WO JP9701041)
Priority Application: JP 9673016 19960328
Designated States: AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE GH HU IL IS KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK TJ TM TR TT UA US UZ VN YU GH KE LS MW SD SZ UG AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG
Publication Language: English
Filing Language: English
Fulltext Word Count: 10599

English Abstract
Disclosed is a sustainedrelease preparation characterized in that it is produced by dispersing in an oil phase a rapidly dried product containing a bioactive polypeptide and a surfactant, and subsequent shaping, and a method of its production.

French Abstract
Cette invention concerne une preparation a liberation prolongee, laquelle est obtenue en dispersant, dans une phase d'huile, un produit seché rapidement et contenant un polypeptide bioactif ainsi qu'un tensioactif, ceci avant de proceder a la mise en forme. Cette invention concerne egalement un procede de production de cette preparation.

9/3,AB/43 (Item 16 from file: 349)
DIALOG(R)File 349:PCT Fulltext

00504345
MODULATORS OF EXPRESSION AND FUNCTION OF LRP IN ALZHEIMER'S DISEASE
MODULATEURS D'EXPRESSION ET DE FONCTION DE LA PROTEINE ASSOCIEE AU RECEPTEUR DE LA LIPOPROTEINE BASSE DENSITE (LRP) DANS LA MALADIE D'ALZHEIMER
Patent Applicant/Assignee:
THE AMERICAN NATIONAL RED CROSS
THE GENERAL HOSPITAL CORPORATION
Inventor(s):
STRICKLAND Dudley K
HYMAN Bradley T
KOUNNAS Maria Z
MOIR Robert D
TANZI Rudolph E

Patent and Priority Information (Country, Number, Date):
  Patent: WO 9704794 A1 19970213
  Application: WO 96US12686 19960729 (PCT/WO US9612686)
  Priority Application: US 951600 19950727; US 951653 19950728
Designated States: CA JP MX AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE
Publication Language: English
Fulltext Word Count: 11475

English Abstract
The present invention broadly relates to the treatment, diagnosis, and prophylactic prevention of Alzheimer's disease. More specifically, the present invention relates to methods and compositions for preventing the endocytosis and cellular internalization of integral membrane amyloid 'beta'-precursor protein (APP) and its subsequent catabolism by blocking or interfering with the association or binding of APP with members of the low density lipoprotein receptor family.

Japanese Abstract
La presente invention se rapporte generalement au traitement, au diagnostic et la prophylaxie de la maladie d'Alzheimer. Plus particulierement, l'invention se rapporte a des procedes et a des compositions pour la prevention de l'endocytose et de l'internalisation cellulaire de la proteine membranaire integrale dite proteine precurseur 'beta' amyloide (APP) et de son catabolisme ulterieur en bloquant ou en interferant avec l'association ou la liaison de l'APP avec des membres de la famille de recepteurs de la lipoproteine basse densite.

9/3,AB/44 (Item 17 from file: 349)
DIALOG(R)File 349:PCT Fulltext

00500819
METHOD OF PRODUCING SUSTAINED-RELEASE PREPARATION
PRODUCTION DE PREPARATIONS A LIBERATION PROLONGEE
Patent Applicant/Assignee:
  TAKEDA CHEMICAL INDUSTRIES LTD
  OKAMOTO Kayoko
  YAMAGATA Yutaka
  IGARI Yasutaka
  MISAKI Masafumi
Inventor(s):
  OKAMOTO Kayoko
  YAMAGATA Yutaka
  IGARI Yasutaka
  MISAKI Masafumi
Patent and Priority Information (Country, Number, Date):
  Patent: WO 9701331 A2-A3 19970116
  Application: WO 96JP1770 19960626 (PCT/WO JP9601770)
  Priority Application: JP 95161204 19950627; JP 96102403 19960424
Designated States: AL AM AU AZ BB BG BR BY CA CN CZ EE GE HU IL IS KG KR KZ LK LR LT LV MD MN MX NO NZ PL RO RU SG SI SK TJ TM TR TT UA US UZ VN KE LS MW SD SZ UG BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE CF CG CI CM GA GN ML MR NE SN TD TG
Publication Language: English
Fulltext Word Count: 10798

English Abstract
This invention provides a sustained-release preparation comprising a %biodegradable% polymer metal salt and bioactive polypeptide, with enhanced entrapment of the bioactive polypeptides, a suppression of initial burst, and a constant long-term release of the bioactive polypeptides.

Japanese Abstract

Cette invention concerne une preparation a liberation prolongee comprenant un sel metallique de polymere %biodegradable% et un polypeptide bioactif, avec amelioration de piegeage des polypeptides bioactifs, suppression de la bouffee de depart et liberation constante a long terme des polypeptides bioactifs.

9/3,AB/45 (Item 18 from file: 349)
DIALOG(R)File 349:PCT Fulltext

00444380
NOVEL TARGETED COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC USE
NOUVELLES COMPOSITIONS CIBLEES, DESTINEES A UNE UTILISATION DIAGNOSTIQUE ET THERAPEUTIQUE
Patent Applicant/Assignee:
IMARx PHARMACEUTICAL CORP
UNGER Evan C
SHEN Dekang
WU Guanli
Inventor(s):
UNGER Evan C
SHEN Dekang
WU Guanli
Patent and Priority Information (Country, Number, Date):
Patent: WO 9640285 A1 19961219
Application: WO 96US9938 19960606 (PCT/WO US9609938)
Priority Application: US 95497684 19950607; US 96640464 19960501
Designated States: AU CA CN JP US AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE
Publication Language: English
Fulltext Word Count: 60067

English Abstract
Novel targeted compositions which may be used for diagnostic and therapeutic use. The compositions may comprise a lipid, a protein or a polymer and a gas, in combination with a targeting ligand. The targeting ligand targets tissues, cells or receptors, including myocardial cells, endothelial cells, epithelial cells, tumor cells and the glycoprotein GPIIbIIIa receptor. The contrast media can be used in conjunction with diagnostic imaging, such as ultrasound, as well as therapeutic applications, such as therapeutic ultrasound.

Japanese Abstract
Ces nouvelles compositions ciblees, que l'on peut utiliser a des fins diagnostiques et therapeutiques, peuvent comprendre un lipide, une proteine ou un polymere, ainsi qu'un gaz, en combinaison avec un ligand de ciblage. Ce ligand cible des tissus, des cellules ou des recepteurs, notamment des cellules myocardiques, endotheliales, epitheliales, tumorales, ainsi que le recepteur de la glycoproteine GPIIbIIIa. On peut utiliser ces substances de contraste conjointement avec l'imagerie diagnostique, telle que l'echographie, ainsi qu'avec des applications therapeutiques, telles que l'ultrasonotherapie.

9/3,AB/46 (Item 19 from file: 349)
DIALOG(R)File 349:PCT Fulltext

00444205
TREATMENT OF A TRABECULAR MESHWORK WHOSE CELLS ARE SUBJECT OT INHIBITION OF CELL DIVISION WITH NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
TRAITEMENT PAR ANTI-INFLAMMATOIRES NON STEROIDIENS DE TISSUS TRABECULAIRES DONT LES CELLULES SONT SUJETTES A L'INHIBITION DE LA DIVISION CELLULAIRE
Patent Applicant/Assignee:

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Inventor(s):
POLANSKY Jon R
BLOOM Ernest
FAUSS Donald J
Patent and Priority Information (Country, Number, Date):
Patent: WO 9640103 A1 19961219
Application: WO 96US7401 19960521 (PCT/WO US9607401)
Priority Application: US 95486255 19950607
Designated States: AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI TM TR TT UA UG UZ VN KE LS MW SD SZ UG AM AZ BY KG KZ MD RU TJ TM AT BE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE TG
Publication Language: English
Fulltext Word Count: 9294

English Abstract
The invention concerns the recognition that certain non-steroidal anti-inflammatory agents can overcome or ameliorate limitations on trabecular meshwork cell division produced by environmental stresses (e. g., oxidative or phagocytic injury, or glucocorticoid exposure), and thus can be used to prevent or treatloss of trabecular cells found in certain forms of glaucoma and in normal aging. The use of such non- steroidal anti-inflammatory agents can ameliorate the severity, or prevent glaucoma.

Japanese Abstract
Cette invention concerne la capacite de certains agents anti-inflammatoires non steroidiens de supprimer ou de reduire les limitations entravant la division cellulaire se produisant dans un tissu trabeculaire a cause de contraintes du milieu environnant (par exemple, blessures oxydantes ou phagocytaires, ou exposition a des glucocorticoides). Ces agents peuvent ainsi etre utilises afin de prevenir ou de traiter la perte de cellules trabeculaires que l'on rencontre dans certaines formes de glaucomes ou lors du processus normal de vieillissement. L'utilisation de tels agents anti-inflammatoires non steroidiens permet de limiter la gravite des glaucomes ou de les prevenir.

9/3,AB/47 (Item 20 from file: 349)
DIALOG(R)File 349:PCT Fulltext

00444204
NON-STEROIDAL ANTI-INFLAMMATORY DRUGS FOR THE CYTO-PROTECTION OF THE TRABECULAR MESHWORK
MEDICAMENTS NON STEROIDIENS ANTI-INFLAMMATOIRES DESTINES A LA CYTOPROTECTION DE TISSUS TRABECULAIRES
Patent Applicant/Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Inventor(s):
POLANSKY Jon R
BLOOM Ernest
FAUSS Donald J
Patent and Priority Information (Country, Number, Date):
Patent: WO 9640102 A1 19961219
Application: WO 96US7340 19960521 (PCT/WO US9607340)
Priority Application: US 95479185 19950607
Designated States: AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI TM TR TT UA UG UZ VN KE LS MW SD SZ UG AM AZ BY KG KZ MD RU TJ TM AT BE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE TG
Publication Language: English
Fulltext Word Count: 9726

English Abstract
The invention concerns the recognition that certain non-steroidal anti-inflammatory agents produce cytoprotective effects on trabecular cells, and thus can be used to prevent injury of the cells and treat the loss of trabecular cells caused by oxidative or other forms of injury to the cells. Such treatment can ameliorate the severity or prevent glaucoma.

Japanese Abstract
Cette invention concerne la capacite de certains agents non steroidiens et anti-inflammatoires a produire des effets cytoprotecteurs sur des cellules trabeculaires. Ces medicaments peuvent etre employes afin de prevenir des lesions des cellules, et de traiter la perte de cellules trabeculaires engendree par des lesions de type oxydante ou autre de ces cellules. Un tel traitement permet de limiter la gravite des glaucomes ou de les prevenir.

9/3,AB/48 (Item 21 from file: 349)
DIALOG(R)File 349:PCT Fulltext

00418796
METHODS FOR THE DIAGNOSIS OF GLAUCOMA
PROCEDES DE DIAGNOSTIC DU GLAUCOME
Patent Applicant/Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Inventor(s):
NGUYEN Thai D
POLANSKY Jon R
HUANG Weidong
Patent and Priority Information (Country, Number, Date):
Patent: WO 9614411 A1 19960517
Application: WO 95US14024 19951027 (PCT/WO US9514024)
Priority Application: US 94336235 19941103
Designated States: AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ UA UG UZ VN KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL BF BJ CF CG CI CM GA GN ML MR NE SN TD TG
Publication Language: English
Fulltext Word Count: 16187

English Abstract
A glucocorticoid-induced protein, TIGR, that is produced by cells of the trabecular meshwork can be used to diagnose glaucoma. The TIGR protein, anti-TIGR antibodies, and TIGR encoding sequences also provide a diagnostic for glaucoma and its related diseases.

Japanese Abstract
La presente invention concerne une proteine induite par un glucocorticoide, la TIGR, produite par les cellules du maillage trabeculaire, qui peut servir a diagnostiquer un glaucome. Ladite proteine TIGR, les anticorps anti-TIGR, ainsi que les sequences d'ADN codant pour la proteine TIGR offrent egalement un moyen de diagnostic du glaucome et des maladies associees a celui-ci.

9/3,AB/49 (Item 22 from file: 349)
DIALOG(R)File 349:PCT Fulltext

00417444
SENESCENT CELL-DERIVED INHIBITORS OF DNA SYNTHESIS
INHIBITEURS DE SYNTHESE D'ADN PRODUITS DANS DES CELLULES SENESCENTES
Patent Applicant/Assignee:

BAYLOR COLLEGE OF MEDECINE
SENNES DRUG INNOVATIONS INC
Inventor(s):
SMITH James R
DRUTZ David G
WILSON Deborah R
ZUMSTEIN Louis A
Patent and Priority Information (Country, Number, Date):
Patent: WO 9612506 A1 19960502
Application: WO 95US13766 19951024 (PCT/WO US9513766)
Priority Application: US 94327874 19941024; WO 95US6451 19950523; US 95524218 19950906
Designated States: AU CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
Publication Language: English
Fulltext Word Count: 51728

English Abstract
The use of liposomal formulations, particularly formulations of positively charged and neutral lipids facilitates cellular uptake of SDI molecules. The transcription and/or expression of SDI-1-encoding nucleic acid molecules is facilitated by constructs that contain intervening untranslated regions.

Japanese Abstract
L'utilisation de formulations liposomiques, en particulier, des formulations de lipides neutres et positivement charges facilite le captage cellulaire de molecules d'inhibiteurs produits dans des cellules senescentes (SDI). La transcription et/ou l'expression de molecules d'acide nucleique codant SDI-1 est facilitee par des produits de recombinaison contenant des regions intervenantes non traduites.

9/3,AB/50 (Item 23 from file: 349)
DIALOG(R)File 349:PCT Fulltext

00412501
SYNTHETIC GANGLIOSIDE DERIVATIVES
DERIVES SYNTHETIQUES DE GANGLIOSIDES
Patent Applicant/Assignee:
LADISCH Stephan
Inventor(s):
LADISCH Stephan
HASEGAWA Akira
Patent and Priority Information (Country, Number, Date):
Patent: WO 9608257 A1 19960321
Application: WO 95US11670 19950914 (PCT/WO US9511670)
Priority Application: US 94305832 19940914
Designated States: AM AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU IS JP KE KG KP KR LU LV MD MG MN MW NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG UZ VN SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI GN ML MR NE SN TD TG
Publication Language: English
Fulltext Word Count: 9195

English Abstract
Compositions of matter comprising glycosphingolipids useful for suppressing an immune response having formula (I) wherein x is (a) or (b) or H; wherein Y is (c) or H; wherein m is 10 to 20; and wherein n is 1 to 14. Also presented are methods for suppressing an immune response in an animal employing glycosphingolipids as shown above. Synthetic gangliosides having artificial hydrophobic anchors, useful for suppressing an immune response having formula (II) wherein A is a carbohydrate moiety of a ganglioside, n is 5 to 20 and m is 5 to 20. Also presented are methods for suppressing an immune response in an animal and compositions of matter employing synthetic gangliosides having artificial

hydrophobic anchors, as shown above. Simplified carbohydrate moiety-gangliosides, useful for suppressing an immune response according to formula (III) wherein B is a ceramide moiety of a ganglioside. Also presented are methods for suppressing an immune response in an animal and compositions of matter employing simplified carbohydrate moiety-ganglioside as shown above.

Japanese Abstract

Compositions comprenant des glycosphingolipides permettant de supprimer une reponse immunitaire et repondant a la formule (I) dans laquelle x represente (a) ou (b) ou H; Y est (c) ou H; m est compris entre 10 et 20 inclus et n est compris entre 1 et 14 inclus. Des procedes de suppression d'une reponse immunitaire chez l'animal a l'aide desdits glycosphingolipides sont egalement decrits. Des gangliosides synthetiques ayant des supports d'adherence hydrophobes artificiels, permettant de supprimer une reponse immunitaire, repondant a la formule (II) dans laquelle A est une fraction hydrate de carbone d'un ganglioside, n est compris entre 5 et 20 inclus et m est compris entre 5 et 20 inclus sont encore decrits. La presente invention concerne de surcroit des procedes de suppression de la reponse immunitaire chez un animal et des compositions a cet effet contenant des gangliosides synthetiques contenant des supports d'adherence hydrophobes artificiels decrits ci-dessus. Elle concerne aussi des gangliosides a fraction hydrate de carbone simplifies permettant de supprimer une reponse immunitaire, et repondant a la formule (III) dans laquelle B est une fraction ceramide d'un ganglioside. Elle concerne enfin des procedes de suppression de la reponse immunitaire chez un animal et des compositions contenant des gangliosides a fraction hydrate de carbone simplifies decrits ci-dessus.

9/3,AB/51 (Item 24 from file: 349)
DIALOG(R)File 349:PCT Fulltext

00408311

SOLID DELIVERY SYSTEMS FOR CONTROLLED RELEASE OF MOLECULES INCORPORATED THEREIN AND METHODS OF MAKING SAME

SYSTEMES D'ADMINISTRATION DE SUBSTANCES SOLIDES, POUR LA LIBERATION CONTROLEE DE MOLECULES INCORPOREES DANS CES SUBSTANCES ET PROCEDES DE FABRICATION DE CES SYSTEMES

Patent Applicant/Assignee:
QUADRANT HOLDINGS CAMBRIDGE LIMITED
ROSER Bruce Joseph
COLACO Camilo
JERROW Mohamed Abdel Zahra
BLAIR Julian Alexander
KAMPINGA Jaap
WARDELL James Lewis
DUFFY John Alistair

Inventor(s):
ROSER Bruce Joseph
COLACO Camilo
JERROW Mohamed Abdel Zahra
BLAIR Julian Alexander
KAMPINGA Jaap
WARDELL James Lewis
DUFFY John Alistair

Patent and Priority Information (Country, Number, Date):
Patent: WO 9603978 A1 19960215
Application: WO 95GB1861 19950804 (PCT/WO GB9501861)
Priority Application: GB 9415810 19940804; US 94349029 19941202
Designated States: AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT US UZ VN KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE CF CG CI CM GA GN ML MR NE SN TD TG
Publication Language: English

Fulltext Word Count: 20535

English Abstract
The present invention encompasses solid dose delivery systems for administration of guest substances. Preferred delivery systems are suitable for delivery of bioactive materials to subcutaneous and intradermal, intramuscular, intravenous tissue, the delivery system being sized and shaped for penetrating the epidermis. The delivery systems comprise a vitreous vehicle loaded with the guest substance and capable of releasing the guest substance in situ at various controlled rates. The present invention further includes methods of making and using the solid dose delivery systems.

Japanese Abstract
Cette invention se rapporte a des systemes d'apport de doses de substances solides, qui servent a l'administration de substances hotes incorporees dans ces doses. Les systemes d'administration preferes de cette invention se pretent a l'apport de matieres bioactives dans des tissus intraveineux, intramusculaires, sous-cutanes et intradermiques, la taille et la forme de ce systeme d'apport etant concues pour lui permettre de penetrer dans l'epiderme. Ces systemes d'apport comprennent un excipient vitreux charge de la substance hote et capable de liberer cette substance hote in situ a divers taux controles. Cette invention se rapporte en outre a des procedes pour fabriquer et utiliser ces systemes d'administration de doses de substances solides.

9/3,AB/52 (Item 25 from file: 349)
DIALOG(R)File 349:PCT Fulltext

00405237
TARGETED GENE DELIVERY SYSTEM
SYSTEME DE TRANSPORT DE GENE CIBLE
Patent Applicant/Assignee:
THE JOHNS HOPKINS UNIVERSITY
Inventor(s):
TRUONG Vu L
AUGUST Thomas
LEONG Kam W
Patent and Priority Information (Country, Number, Date):
Patent: WO 9600295 A1 19960104
Application: WO 95US7857 19950623 (PCT/WO US9507857)
Priority Application: US 94265966 19940627
Designated States: AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UZ VN KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF CG CI CM GA GN ML MR NE SN TD TG
Publication Language: English
Fulltext Word Count: 4147

English Abstract
A target-specific gene delivery system is made of enzymatically degradable gelatin and nucleic acids (DNA or RNA) %microparticles% with a linking moiety or a targeting ligand attached to the surface. The delivery system can be made by a simple method. Targeting ligands can be attached to the %microparticle% directly or via a linking moiety. The linkage design allows the attachment of any molecule onto the %microparticle% surface including antibodies, cell adhesion molecules, hormones and other cell-specific ligands.

Japanese Abstract
Systeme de transport d'un gene specifique d'une cible, compose de microparticules de gelatine degradable enzymatiquement et d'acides nucleiques (ADN ou ARN) comportant une fraction de liaison ou un ligand de ciblage lies a la surface. Ce systeme de transport peut etre realise

par un procede simple. Des ligands de ciblage peuvent etre fixes sur une microparticule directement ou par l'intermediaire d'une fraction de liaison. La structure de la liaison permet de fixer toute molecule sur la surface d'une microparticule, y compris des anticorps, des molecules d'adherence cellulaire, des hormones et d'autres ligands a specificite cellulaire.

9/3,AB/53 (Item 26 from file: 349)
DIALOG(R)File 349:PCT Fulltext

00397013
AQUEOUS SOLVENT ENCAPSULATION METHOD, APPARATUS AND %MICROCAPSULES%
PROCEDE D'ENCAPSULATION PAR SOLVANT AQUEUX, APPAREIL ET %MICROCAPSULES%
Patent Applicant/Assignee:
TEMPLE UNIVERSITY
CHILDREN'S HOSPITAL OF PHILADELPHIA
CLARK Fred H
OFFIT Paul A
MOSER Charlotte A
SPEAKER Tully J
Inventor(s):
CLARK Fred H
OFFIT Paul A
MOSER Charlotte A
SPEAKER Tully J
Patent and Priority Information (Country, Number, Date):
Patent: WO 9528227 A1 19951026
Application: WO 95US4711 19950417 (PCT/WO US9504711)
Priority Application: US 94228481 19940415; US 94229283 19940418; US 94229520 19940418
Designated States: AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT US US US UZ VN KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL BF BJ CF CG CI CM GA GN ML MR NE SN TD TG
Publication Language: English
Fulltext Word Count: 20950

English Abstract
A %microcapsule% substantially free from non-aqueous contaminants comprising an aqueous core surrounded by a capsular wall, the capsular wall being the reaction product of a selected water soluble anionic polymer or salt thereof with a selected water soluble amine or salt thereof, the selected anionic polymer and amine having the property that, when droplets of an aqueous solution of the selected polymer are introduced into an aqueous solution of the selected amine, stable %microcapsules% of the amine salt of the anionic polymer are formed. The aqueous core of the %microcapsule% may contain any of various active ingredients, including immunogenic agents such as rotavirus. A method and apparatus for making the %microcapsules%, including %microcapsules% comprising active agents, as well as their method of use, are also disclosed.

Japanese Abstract
La presente invention concerne une %microcapsule% essentiellement exempte de contaminants non aqueux et se composant d'un noyau aqueux entoure d'une paroi capsulaire. Ladite paroi capsulaire est le produit de reaction d'un polymere anionique hydrosoluble selectionne, ou de l'un de ses sels, avec une amine hydrosoluble selectionnee, ou l'un de ses sels. Le polymere anionique selectionne et l'amine sont caracterises par la formation de %microcapsules% stables du sel d'amine du polymere anionique lors de l'introduction des gouttelettes d'une solution aqueuse du polymere selectionne dans une solution aqueuse de l'amine selectionnee. Le noyau aqueux de la %microcapsule% peut contenir l'un quelconque des principe actifs, y compris des agents immunogenes tels qu'un rotavirus.

L'invention concerne egalement un appareil et un procede de fabrication des %microcapsules%, y compris des %microcapsules% renfermant des agents actifs, ainsi que leurs procedes d'utilisation.

9/3,AB/54 (Item 27 from file: 349)
DIALOG(R)File 349:PCT Fulltext

00385224
CONTROLLED RELEASE OF PHARMACEUTICALLY ACTIVE SUBSTANCES FOR IMMUNOTHERAPY
LIBERATION CONTROLEE DE SUBSTANCES PHARMACEUTIQUEMENT ACTIVES POUR L'IMMUNOTHERAPIE
Patent Applicant/Assignee:
JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE
Inventor(s):
PARDOLL Drew
AZHARI Rosa
LEONG Kam W
GOLUMBEK Paul
JAFFEE Elizabeth
LEVITSKY Hyam
LAZENBY Audrey
Patent and Priority Information (Country, Number, Date):
Patent: WO 9516464 A1 19950622
Application: WO 94US14642 19941213 (PCT/WO US9414642)
Priority Application: US 93167562 19931214
Designated States: CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
Publication Language: English
Fulltext Word Count: 7805

English Abstract
A method of stimulating a systemic immune response to a tumor cell or %antigen% associated with a pathogen by administering a mixture of a controlled release vehicle containing an immunopotentiating agent and %antigen% is described.

Japanese Abstract
L'invention concerne un procede pour stimuler une reponse immunitaire systematique sur une cellule tumorale ou un antigene associe a un pathogene. Ce procede consiste a administrer un melange d'un vehicule a liberation controlee contenant un agent renforcant l'immunite et un antigene.

9/3,AB/55 (Item 28 from file: 349)
DIALOG(R)File 349:PCT Fulltext

00382576
BIOCOMPATIBLE OCULAR IMPLANTS
IMPLANTS OCULAIRES BIOCOMPATIBLES
Patent Applicant/Assignee:
OCULEX PHARMACEUTICALS INC
Inventor(s):
WONG Vernon G
KOCHINKE Frank
Patent and Priority Information (Country, Number, Date):
Patent: WO 9513765 A1 19950526
Application: WO 94US12898 19941109 (PCT/WO US9412898)
Priority Application: US 93153184 19931115
Designated States: AU CA CN JP KR RU AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
Publication Language: English
Fulltext Word Count: 9405

POWELL Michael Frank
Patent and Priority Information (Country, Number, Date):
Patent: WO 9511008 A2-A3 19950427
Application: WO 94US11674 19941013 (PCT/WO US9411674)
Priority Application: US 93141341 19931022; US 93143332 19931025
Designated States: AU CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
Publication Language: English
Fulltext Word Count: 16058

English Abstract
Methods and compositions are provided for the encapsulation of adjuvants in PLGA microspheres for use as vaccines. Mixtures of microspheres are provided which release adjuvant at desired intervals to provide boosts with adjuvant.

Japanese Abstract
L'invention concerne des procedes et des compositions s'utilisant dans la microencapsulation d'adjuvants dans des microspheres de poly(D-L-lactide-coglycolide) (PLGA) utilisees comme vaccins. L'invention concerne en outre des melanges de microspheres qui liberent lesdits adjuvants a intervalles voulus pour produire des effets de rappel.

9/3,AB/58 (Item 31 from file: 349)
DIALOG(R)File 349:PCT Fulltext

00375611
SENESCENT CELL-DERIVED INHIBITORS OF DNA SYNTHESIS
INHIBITEURS DE SYNTHESE D'ADN DERIVES DE CELLULES SENESCENTES
Patent Applicant/Assignee:
BAYLOR COLLEGE OF MEDICINE
SMITH James R
Inventor(s):
SMITH James R
Patent and Priority Information (Country, Number, Date):
Patent: WO 9506415 A1 19950309
Application: WO 94US9700 19940826 (PCT/WO US9409700)
Priority Application: US 93113372 19930830; US 93153564 19931117; US 94160814 19940103; US 94203535 19940225; US 94229420 19940415; US 94268439 19940630; US 94274535 19940713
Designated States: AU CA JP US AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
Publication Language: English
Fulltext Word Count: 44781

English Abstract
An expression vector cDNA library derived from senescent cells has been used to isolate cDNA clones that encode inhibitors of DNA synthesis. Such inhibitors play a role in cellular senescence, aging and neoplasia. Antisense nucleic acids reduce the inhibition of DNA synthesis. The invention concerns such molecules, their inhibitors, antagonists and derivatives. The invention also concerns diagnostic, therapeutic and in vitro uses for all such agents.

Japanese Abstract
Une banque d'ADNc de vecteur d'expression derivee de cellules senescentes a ete utilisee pour isoler des clones d'ADNc codant des inhibiteurs de la synthese d'ADN. De tels inhibiteurs jouent un role dans la senescence, le vieillissement et la neoplasie cellulaires. Des acides nucleiques antisens reduisent l'inhibition de la synthese d'ADN. L'invention se rapporte a de telles molecules ainsi qu'a leurs inhibiteurs, antagonistes et derives. L'invention se rapporte egalement aux utilisations diagnostiques, therapeutiques et in vitro de tous ces agents.

9/3,AB/59 (Item 32 from file: 349)
DIALOG(R)File 349:PCT Fulltext

00363196
ENCAPSULATION OF NUCLEIC ACIDS WITH CONJUGATES THAT FACILITATE AND TARGET CELLULAR UPTAKE AND GENE EXPRESSION
ENCAPSULATION D'ACIDES NUCLEIQUES AVEC DES CONJUGUES QUI FACILITENT ET CIBLENT L'ABSORPTION CELLULAIRE ET L'EXPRESSION GENIQUE
Patent Applicant/Assignee:
MEDISORB TECHNOLOGIES INTERNATIONAL LP
Inventor(s):
McELLIGOTT Sandra Gertrude
AMOS Michael David
Patent and Priority Information (Country, Number, Date):
Patent: WO 9423738 A1 19941027
Application: WO 94US4239 19940419 (PCT/WO US9404239)
Priority Application: US 9347536 19930419
Designated States: AU CA JP NZ AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
Publication Language: English
Fulltext Word Count: 13082

English Abstract
This invention is a method for encapsulating nucleic acids linked to or co-existing with other molecules that facilitate the uptake and integration of genetic material into living cells by means of slow-release of DNA/RNA or oligonucleotides combined with cell surface ligands/proteins/transcription factors and antibodies. Compositions for use with this method are disclosed.

Japanese Abstract
Procede d'encapsulation d'acides nucleiques lies ou co-existants avec d'autres molecules qui facilitent l'absorption et l'integration de materiel genetique dans des cellules vivantes a l'aide d'ADN/ARN a liberation lente ou d'oligonucleotides combines a des facteurs de transcription/proteines/ligands de surface cellulaire et d'anticorps. On decrit egalement des compositions destinees a etre utilisees avec ce procede.

9/3,AB/60 (Item 33 from file: 349)
DIALOG(R)File 349:PCT Fulltext

00315724
GANGLIOSIDES WITH IMMUNOSUPPRESSIVE CERAMIDE MOIETIES
GANGLIOSIDES COMPRENANT DES FRACTIONS DE CERAMIDES A EFFET IMMUNOSUPPRESSEUR
Patent Applicant/Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Inventor(s):
LADISCH Stephan
Patent and Priority Information (Country, Number, Date):
Patent: WO 9302686 A1 19930218
Application: WO 92US6358 19920730 (PCT/WO US9206358)
Priority Application: US 91738591 19910731
Designated States: CA JP AT BE CH DE DK ES FR GB GR IT LU MC NL SE
Publication Language: English
Fulltext Word Count: 8811

English Abstract
A method for suppressing immune responses in animals by administering a mixture of gangliosides to the animal where the gangliosides have heterogeneous ceramide structures containing fatty acid portions with carbon chain lengths of 21-30 or less than 18 carbon atoms. Ganglioside

mixtures which are homogeneous with respect to the fatty acid portion are also effective immunosuppressive agents when the carbon chain length of the fatty acid portion is less than 18. Compositions containing the above specified ganglioside mixtures are also disclosed.

Japanese Abstract
Procede de suppressions de reponses immunitaires chez des animaux par administration d'un melange de gangliosides presentant des structures heterogene de ceramides contenant des parties d'acide gras avec des longueurs de chaine carbonee de 21 a 30 ou inferieures a 18 atomes de carbone. Des melanges de gangliosides qui sont homogenes par rapport a la partie d'acide gras sont egalement des agents immunosuppresseurs efficaces lorsque la longueur de la chaine carbonee de la partie d'acide gras est inferieure a 18. L'invention concerne egalement des compositions contenant lesdits melanges de gangliosides.

9/3,AB/61 (Item 34 from file: 349)
DIALOG(R)File 349:PCT Fulltext

00307184
GANGLIOSIDES WITH IMMUNOSUPPRESSIVE ACTIVITY
GANGLIOSIDES PRESENTANT UNE ACTIVITE D'IMMUNODEPRESSION
Patent Applicant/Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Inventor(s):
LADISCH Stephen
Patent and Priority Information (Country, Number, Date):
Patent: WO 9217189 A1 19921015
Application: WO 92US2624 19920327 (PCT/WO US9202624)
Priority Application: US 91677437 19910329
Designated States: AT BE CA CH DE DK ES FR GB GR IT JP LU MC NL SE
Publication Language: English
Fulltext Word Count: 7504

English Abstract
A method for suppressing immune responses in animals by administering gangliosides to the animal. Gangliosides having terminal sialic acid groups are disclosed as being especially effective as immunosuppressive agents. The especially effective immunosuppressive gangliosides include GM4 and GM5. Ganglioside compositions for use in suppressing immune responses are also disclosed.

Japanese Abstract
Procede servant a deprimer la reponse immunitaire chez les animaux par l'administration de gangliosides. Les gangliosides possedant des groupes d'acide salivaire en fin de chaine sont tout particulierement efficaces en tant qu'agents immunodepresseurs. Le GM4 et le GM5 comptent parmi les gangliosides immunodepresseurs particulierement efficaces. On a egalement prevu des compositions de gangliosides destinees a la depression des reponses immunitaires.

9/3,AB/62 (Item 1 from file: 348)
DIALOG(R)File 348:European Patents

00682246
A sustained release composition comprising a multivalent cation cross-linked algenate combined with a polyacrylic acid
Zusammensetzung mit verzogerter Wirkstoffabgabe enthaltend ein multivalentes Kation verzetztes Alginat kombiniert mit einem Polyacrylsaure
Composition a liberation prolongee comprenant un alginate reticule multivalent cationique combine avec un acide polyacrylique

PATENT ASSIGNEE:
BRISTOL-MYERS SQUIBB COMPANY, (205416), 345 Park Avenue, New York, N.Y. 10154-0037, (US), (applicant designated states: AT;BE;CH;DE;DK;ES;FR;GB;GR;IE;IT;LI;LU;MC;NL;PT;SE)
UNIVERSITY OF WASHINGTON, (2243810), Office of Technology Transfer, 1107 NE 45th Street, Suite 200, Seattle, WA 98105, (US), (applicant designated states: AT;BE;CH;DE;DK;ES;FR;GB;GR;IE;IT;LI;LU;MC;NL;PT;SE)
INVENTOR:
Gombotz, W. R., 6406 N.E. 129th Place, Kirkland, Washington 98034, (US)
Mumper, R. J., 1812 Crooked Creed Road, Greenville, North Carolina 27858, (US)
Bouchard, L. S., 2223 Benson Road S Apt. T202, Renton, Washington 98055, (US)
Hoffman, A. S., 4528 West Laurel Drive N.E., Seattle, Washington 98105, (US)
LEGAL REPRESENTATIVE:
White, Martin Paul et al (74783), Kilburn & Strode, 30 John Street, London WC1N 2DD, (GB)
PATENT (CC, No, Kind, Date): EP 652015 A2 950510 (Basic)
EP 652015 A3 950802
EP 652015 B1 970319
APPLICATION (CC, No, Date): EP 94307259 941004;
PRIORITY (CC, No, Date): US 138367 931015
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE
INTERNATIONAL PATENT CLASS: A61K-047/36; A61K-047/38; A61K-047/32; A61K-038/00; A61K-038/27;

ABSTRACT EP 652015 A2
Alginate beads are employed as a site specific oral delivery system for cationic therapeutic agents, such as TGF-b(sub 1), designed to target the agents to the luminal side of the small intestine. Improved delivery of bioactive material is obtained by: 1) incorporating selected polyanions in the alginate beads to shield the cationic therapeutic agent from interaction with alginate and/or 2) acid treating alginate beads containing the therapeutic agents to reduce the molecular weight of alginate and its interaction with the agents. Enhanced bioactivity of therapeutic agents released from the alginate is attributed to the ability of polyacrylic acid to shield the agents from interaction with lower molecular fragments of acid treated alginate.
ABSTRACT WORD COUNT: 114

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPAB95	363
SPEC A	(English)	EPAB95	8970
Total word count - document A			9333
Total word count - document B			0
Total word count - documents A + B			9333

9/3,AB/63 (Item 2 from file: 348)
DIALOG(R)File 348:European Patents

00269010
Improved method of obtaining immune regulatory factors by mammal immunization.
Verfahren zum Erhalten von immunregulierenden Faktoren mittels Saugetierimmunisierung.
Methode d'obtention de facteurs immunoregulateurs par immunisation de mammiferes.
PATENT ASSIGNEE:
THE STOLLE RESEARCH AND DEVELOPMENT CORPORATION, (285440), 6990 Cornell Road, Cincinnati Ohio 45242, (US), (applicant designated states:

AT;BE;CH;DE;FR;GB;IT;LI;LU;NL;SE)
INVENTOR:
Beck, Lee R., 2550 Dunmore Place, Birmingham, AL 35226, (US)
LEGAL REPRESENTATIVE:
Burford, Anthony Frederick (28961), W.H. Beck, Greener & Co. 7 Stone Buildings Lincoln's Inn, London WC2A 3SZ, (GB)
PATENT (CC, No, Kind, Date): EP 300102 A1 890125 (Basic)
EP 300102 B1 930324
APPLICATION (CC, No, Date): EP 87306455 870721;
PRIORITY (CC, No, Date): EP 87306455 870721
DESIGNATED STATES: AT; BE; CH; DE; FR; GB; IT; LI; LU; NL; SE
INTERNATIONAL PATENT CLASS: A61K-039/00; A61K-009/52; A61K-039/40; A61K-037/02; A61K-035/20

ABSTRACT EP 300102 A1
Immune regulatory factors, eg. antibodic and lymphokinens, are obtained by collecting or extracting immune regulatory factors containing substances, eg. milk, from mammals, especially bovids, immunized by administering an antigenic substance incorporated within a shaped structure of a biocompatible matrix material. The matrix material causes controlled release of the antigenic substance thereby prolonging antigenic activity within the treated animal.
ABSTRACT WORD COUNT: 62

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPBBF1	681
CLAIMS B	(German)	EPBBF1	584
CLAIMS B	(French)	EPBBF1	648
SPEC B	(English)	EPBBF1	4781
Total word count - document A			0
Total word count - document B			6694
Total word count - documents A + B			6694

9/3,AB/64 (Item 1 from file: 652)
DIALOG(R)File 652:US Patents Fulltext

00835685
Utility
STRUCTURED BIOERODIBLE DRUG DELIVERY DEVICE

PATENT NO.: 3,962,414
ISSUED: June 08, 1976 (19760608)
INVENTOR(s): Michaels, Alan S., Atherton, CA (California), US (United States of America)
ASSIGNEE(s): Alza Corporation, (A U.S. Company or Corporation), Palo Alto , CA (California), US (United States of America)
[Assignee Code(s): 2490]
APPL. NO.: 5-517,982
FILED: October 25, 1974 (19741025)

This is a division of application Ser. No. 248,168, filed Apr. 27, 1972 and now U.S. Pat. No. 3,867,519.

FULL TEXT: 1707 lines

ABSTRACT

A drug delivery device for the continuous and controlled administration of a predetermined therapeutically effective dosage of eye drug to the eye of a mamallian patient over a prolonged period of time. The device meters the

flow of polylactic acid polymer micro-encapsulated eye drug by means of a drug release rate controlling material comprised of an anionic polyvalent metal cation cross-linked polyelectrolyte. The device bioerodes in the biological environment of the patient concurrently with the dispensing or at a point in time after the dispensing of the therapeutically desired amount of drug.

00742120

Utility
BIOERODIBLE DRUG DELIVERY DEVICE

PATENT NO.: 3,867,519
ISSUED: February 18, 1975 (19750218)
INVENTOR(s): Michaels, Alan S., Atherton, CA (California), US (United States of America)
ASSIGNEE(s): Alza Corporation, (A U.S. Company or Corporation), US (United States of America)
[Assignee Code(s): 2490]
APPL. NO.: 5-248,168
FILED: April 27, 1972 (19720427)

FULL TEXT: 1741 lines

ABSTRACT

A drug delivery device for the continuous and controlled administration of a predetermined therapeutically effective dosage of drug to a mamallian patient over a prolonged period of time. The device meters the flow of drug by means of a drug release rate controlling material comprised of an anionic polyvalent metal cation cross-linked polyelectrolyte. The device bioerodes in the biological environment of the patient concurrently with the dispensing or at a point in time after the dispensing of the therapeutically desired amount of drug.

```
et     Items   Description
S1      10515   COACERVATE OR COACERVATION
S2      74108   S1 AND MICROPARTICLE? OR MICROCAPSULE?
S3       5051   S2 AND S1
S4        607   S3 AND BIODEGRADABLE
S5        199   S4 AND ANTIGEN
S6         65   S5 NOT PY>1998
S7         65   RD (unique items)
S8       8644   S7 AND COACERVATE OR COACERVATION
S9         65   S8 AND S7
S10         0   KWIC S9
S11         0   9 KWIC
S12        40   E1-E5
S13        30   RD (unique items)
? s s13 not py>1998

Processing
Processed  10 of  40 files ...
Processing
Processed  30 of  40 files ...
Completed processing all files
              30  S13
        26856778  PY>1998
     S14      22  S13 NOT PY>1998
? t s14/3,ab/1-22

>>>No matching display code(s) found in file(s): 65, 342, 345, 764

 14/3,AB/1     (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2001 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

  132269884    CA: 132(20)269884q    JOURNAL
  Novel oral drug delivery gateways for biotechnology products:
polypeptides and vaccines
  AUTHOR(S): Brayden, David J.; O'Mahony, Daniel J.
  LOCATION: Elan Pharmaceutical Technologies, Trinity College Dublin,
Dublin, Ire., 2
  JOURNAL: Pharm. Sci. Technol. Today  DATE: 1998  VOLUME: 1  NUMBER: 7
  PAGES: 291-299  CODEN: PSTTF8  ISSN: 1461-5347
  PUBLISHER ITEM IDENTIFIER: 1461-5347(98)00075-3  LANGUAGE: English
  PUBLISHER: Elsevier Science Ltd.


 14/3,AB/2     (Item 2 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2001 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

  128248422    CA: 128(20)248422q    JOURNAL
  Binding and uptake of biodegradable poly(dl-lactide) micro- and
nanoparticles in intestinal epithelia
  AUTHOR(S): McClean, Siobhan; Prosser, Ena; Meehan, Eucharia; O'Malley,
Denise; Clarke, Nuala; Ramtoola, Zeibun; Brayden, David
  LOCATION: Elan Pharmaceutical Technologies, Trinity College, Dublin, Ire.
,
  JOURNAL: Eur. J. Pharm. Sci.  DATE: 1998  VOLUME: 6  NUMBER: 2  PAGES:
153-163  CODEN: EPSCED  ISSN: 0928-0987  LANGUAGE: English  PUBLISHER:
Elsevier Science Ireland Ltd.
```

English Abstract
Implants comprising active agents are employed for introduction into a suprachoroidal space or an avascular region of an eye for therapeutic purposes. The administration of drugs is controlled and maintained for long periods of time, while ensuring the substantial absence of significant levels outside the site of administration.

Japanese Abstract
Selon l'invention, on utilise dans un but therapeutique des implants comprenant des agents actifs que l'on introduit dans un espace suprachoroidien ou dans une region avasculaire de l'oeil. La liberation des medicaments dans l'oeil est regulee et maintenue pendant de longues periodes de temps, sans qu'il y ait des niveaux importants de repartition des medicaments en dehors du site d'administration.

9/3,AB/56 (Item 29 from file: 349)
DIALOG(R)File 349:PCT Fulltext

00379839
METHODS AND COMPOSITIONS FOR MICROENCAPSULATION OF ANTIGENS FOR USE AS VACCINES
COMPOSITIONS ET PROCEDES DE MICROENCAPSULATION D'ANTIGENES A UTILISER COMME VACCINS
Patent Applicant/Assignee:
GENENTECH INC
Inventor(s):
CLELAND Jeffrey L
LIM Amy
POWELL Michael Frank
Patent and Priority Information (Country, Number, Date):
Patent: WO 9511010 A1 19950427
Application: WO 94US11753 19941013 (PCT/WO US9411753)
Priority Application: US 93141796 19931022; US 93143555 19931025
Designated States: AU CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
Publication Language: English
Fulltext Word Count: 18322

English Abstract
Methods and compositions are provided for the encapsulation of antigens in PLGA microspheres for use as vaccines. Such microspheres can also contain adjuvants. Mixtures of microspheres are provided which release %antigen% at desired intervals to provide boosts with antigens.

Japanese Abstract
L'invention concerne les compositions et procedes de microencapsulation dans des microspheres de PLGA d'antigenes a utiliser comme vaccins. De telles microspheres peuvent egalement contenir des adjuvants. L'invention concerne egalement des microspheres capables de liberer l'antigene a intervalles specifiques pour assurer une administration par vagues de l'antigene.

9/3,AB/57 (Item 30 from file: 349)
DIALOG(R)File 349:PCT Fulltext

00379837
METHODS AND COMPOSITIONS FOR MICROENCAPSULATION OF ADJUVANTS
PROCEDES ET COMPOSITIONS DE MICROENCAPSULATION D'ADJUVANTS
Patent Applicant/Assignee:
GENENTECH INC
Inventor(s):
CLELAND Jeffrey L
LIM Amy

14/3,AB/3 (Item 3 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

128200510 CA: 128(17)200510q JOURNAL
Heparin absorption across the intestine: effects of sodium N-(8-(2-hydroxybenzoyl)amino)caprylate in rat in situ intestinal instillations and in Caco-2 monolayers
AUTHOR(S): Brayden, David; Creed, Elizabeth; O'connell, Alan; Leipold, Harry; Agarwal, Rajesh; Leone-Bay, Andrea
LOCATION: Elan Pharmaceutical Technologies, Trinity College, Dublin, Ire., 2
JOURNAL: Pharm. Res. DATE: 1997 VOLUME: 14 NUMBER: 12 PAGES: 1772-1779 CODEN: PHREEB ISSN: 0724-8741 LANGUAGE: English PUBLISHER: Plenum Publishing Corp.

14/3,AB/4 (Item 4 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

127185657 CA: 127(14)185657b JOURNAL
A novel in vitro electrophysiological bioassay for transport of loperamide across intestinal epithelia
AUTHOR(S): Brayden, David; Moriarty, Derek; Baird, Alan
LOCATION: Trinity College, Elan Pharmaceutical Technologies, Dubin, Ire.,
JOURNAL: Pharm. Res. DATE: 1997 VOLUME: 14 NUMBER: 7 PAGES: 942-945
CODEN: PHREEB ISSN: 0724-8741 LANGUAGE: English PUBLISHER: Plenum

14/3,AB/5 (Item 5 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

126301309 CA: 126(23)301309v JOURNAL
Human intestinal epithelial cell monolayers as prescreens for oral drug delivery
AUTHOR(S): Brayden, David J.
LOCATION: In Vitro Pharmacology Research Group, Elan Corp., Ire.,
JOURNAL: Pharm. News DATE: 1997 VOLUME: 4 NUMBER: 1 PAGES: 11-15
CODEN: PHNEEP ISSN: 1071-894X LANGUAGE: English PUBLISHER: Harwood

14/3,AB/6 (Item 6 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

126282763 CA: 126(21)282763v BOOK
Current Topics in Peptide Delivery. (Proceedings of CRS Ireland Special Symposium, held at Trinity College, Dublin, Ireland, 20-22 September 1995. (In: J. Controlled Release, 1997; 46(1,2))
AUTHOR(S): Brayden, David; Editor
LOCATION: Neth.
DATE: 1997 PAGES: 198 pp. CODEN: BOOKA7 LANGUAGE: English PUBLISHER: (Elsevier,Amsterdam, Neth.)

14/3,AB/7 (Item 7 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

126152261 CA: 126(12)152261u JOURNAL
Non-antibiotic anti-diarrheal drugs: factors affecting oral bioavailability of berberine and loperamide in intestinal tissue
AUTHOR(S): Baird, Alan W.; Taylor, Cormac T.; Brayden, David J.
LOCATION: Department of Pharmacology, University College Dublin, Dublin,

Ire., 4
JOURNAL: Adv. Drug Delivery Rev. DATE: 1997 VOLUME: 23 NUMBER: 1-3
PAGES: 111-130 CODEN: ADDREP ISSN: 0169-409X LANGUAGE: English
PUBLISHER: Elsevier

14/3,AB/8 (Item 8 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

124270303 CA: 124(20)270303r JOURNAL
Passive transepithelial diltiazem absorption across intestinal tissue leading to tight junction openings
AUTHOR(S): Brayden, D. J.; Creed, E.; Meehan, E.; O'Malley, K. E.
LOCATION: Elan Corporation Research Institute, Trinity College, Dublin, Ire., 2
JOURNAL: J. Controlled Release DATE: 1996 VOLUME: 38 NUMBER: 2,3
PAGES: 193-203 CODEN: JCREEC ISSN: 0168-3659 LANGUAGE: English

14/3,AB/9 (Item 9 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

122151316 CA: 122(13)151316w JOURNAL
Rabbit Peyer's patches: a novel physiological signature in response to cholinomimetics
AUTHOR(S): Brayden, D. J.; Kelly, J. G.
LOCATION: Drug Delivery Research Unit, Trinity College, Dublin, Ire., 2
JOURNAL: Proc. Int. Symp. Controlled Release Bioact. Mater. DATE: 1994
VOLUME: 21ST, PAGES: 276-7 CODEN: PCRMEY ISSN: 1022-0178 LANGUAGE: English

14/3,AB/10 (Item 10 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

122101081 CA: 122(9)101081v JOURNAL
Cultured human sweat gland epithelia: isolation of glands using neutral red
AUTHOR(S): Brayden, David J.; Fitzpatrick, Joan
LOCATION: Elan Corporation Research Institute, Trinity College Dublin, Dublin, Ire.,
JOURNAL: Pharm. Res. DATE: 1995 VOLUME: 12 NUMBER: 1 PAGES: 171-5
CODEN: PHREEB ISSN: 0724-8741 LANGUAGE: English

14/3,AB/11 (Item 11 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

121222732 CA: 121(19)222732w JOURNAL
A distinctive electrophysiological signature from the Peyer's patches of rabbit intestine
AUTHOR(S): Brayden, D. J.; Baird, A. W.
LOCATION: Dep. Pharmacology, Univ. Coll. Dublin, Dublin, Ire.,
JOURNAL: Br. J. Pharmacol. DATE: 1994 VOLUME: 113 NUMBER: 2 PAGES: 593-9 CODEN: BJPCBM ISSN: 0007-1188 LANGUAGE: English

14/3,AB/12 (Item 12 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

121196513 CA: 121(17)196513d CONFERENCE PROCEEDING

A novel electrophysiological signature from the Peyer's patches of rabbit intestine
AUTHOR(S): Brayden, D.J.; Kelly, J.G.
LOCATION: Drug Delivery Res. Unit, Elan Corp., Dublin, Ire.,
JOURNAL: In Vitro Ex Vivo Test Syst. Ration. Drug Des. Delivery, Minutes, Eur. Symp. EDITOR: Crommelin, Daan (Ed), Couvreur, Patrick (Ed), Duchene, Dominique (Ed), DATE: 1994 PAGES: 217-21 CODEN: 60DSAB LANGUAGE: English MEETING DATE: 930000 PUBLISHER: Ed. Sante,Paris, Fr

14/3,AB/13 (Item 13 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

118188701 CA: 118(19)188701m JOURNAL
Stilbenes stimulate T84 chloride secretion by elevating calcium
AUTHOR(S): Brayden, David J.; Krouse, Mauri E.; Law, Tina; Wine, J. J.
LOCATION: Cystic Fibrosis Res. Lab., Stanford Univ., Stanford, CA, 94305-2130, USA
JOURNAL: Am. J. Physiol. DATE: 1993 VOLUME: 264 NUMBER: 2, Pt. 1 PAGES: G325-G333 CODEN: AJPHAP ISSN: 0002-9513 LANGUAGE: English

14/3,AB/14 (Item 14 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

116253513 CA: 116(25)253513b JOURNAL
Cystic fibrosis, the CFTR, and rectifying chloride channels
AUTHOR(S): Wine, J. J.; Brayden, D. J.; Hagiwara, G.; Krouse, M. E.; Law, T. C.; Muller, U. J.; Solc, C. K.; Ward, C. L.; Widdicombe, J. H.; Xia, Y.
LOCATION: Cystic Fibrosis Res. Lab., Stanford Univ., Stanford, CA, USA
JOURNAL: Adv. Exp. Med. Biol. DATE: 1991 VOLUME: 290 NUMBER: Identif. CF (Cystic Fibrosis) Gene PAGES: 253-72 CODEN: AEMBAP ISSN: 0065-2598 LANGUAGE: English

14/3,AB/15 (Item 15 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

115204419 CA: 115(19)204419w JOURNAL
Synchronous transporting activity in epithelial cells in relation to intracellular calcium concentration
AUTHOR(S): Pickles, R. J.; Brayden, D. J.; Cuthbert, A. W.
LOCATION: Dep. Pharmacol., Univ. Cambridge, Cambridge, UK, CB2 1QJ
JOURNAL: Proc. R. Soc. London, Ser. B DATE: 1991 VOLUME: 245 NUMBER: 1312 PAGES: 53-8 CODEN: PRLBA4 ISSN: 0080-4649 LANGUAGE: English

14/3,AB/16 (Item 16 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

114079647 CA: 114(9)79647v JOURNAL
Ion transport in cultured epithelia from human sweat glands: comparison of normal and cystic fibrosis tissues
AUTHOR(S): Brayden, D. J.; Pickles, R. J.; Cuthbert, A. W.
LOCATION: Dep. Pharmacol., Univ. Cambridge, Cambridge, UK, CB2 1QJ
JOURNAL: Br. J. Pharmacol. DATE: 1991 VOLUME: 102 NUMBER: 1 PAGES: 57-64 CODEN: BJPCBM ISSN: 0007-1188 LANGUAGE: English

14/3,AB/17 (Item 17 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

112176455 CA: 112(19)176455x JOURNAL
Altered sensitivity to amiloride in cystic fibrosis. Observations using cultured sweat glands
AUTHOR(S): Cuthbert, A. W.; Brayden, D. J.; Dunne, A.; Smyth, R. L.; Wallwork, J.
LOCATION: Dep. Pharmacol., Univ. Cambridge, Cambridge, UK, CB2 1QJ
JOURNAL: Br. J. Clin. Pharmacol. DATE: 1990 VOLUME: 29 NUMBER: 2
PAGES: 227-34 CODEN: BCPHBM ISSN: 0306-5251 LANGUAGE: English

14/3,AB/18 (Item 18 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

112005395 CA: 112(1)5395y JOURNAL
Thapsigargin, a new calcium-dependent epithelial anion secretagogue
AUTHOR(S): Brayden, D. J.; Hanley, M. R.; Thastrup, O.; Cuthbert, A. W.
LOCATION: Dep. Pharmacol., Univ. Cambridge, Cambridge, UK, CB2 1QJ
JOURNAL: Br. J. Pharmacol. DATE: 1989 VOLUME: 98 NUMBER: 3 PAGES: 809-16 CODEN: BJPCBM ISSN: 0007-1188 LANGUAGE: English

14/3,AB/19 (Item 1 from file: 65)
DIALOG(R)File 65:Inside Conferences

01520816 INSIDE CONFERENCE ITEM ID: CN015098237
Berberine, Enhancement of flux of a poorly absorbed anti- diarrhoeal agent as indicated by electrogenic ion transport in rat colon and T84
%Brayden, D. J.%; Bourke, E.; Baird, A. W.
CONFERENCE: Formulation of poorly-available drugs for oral administration -European symposium
P: 191-194
France, Editions de Sante, 1996
ISBN: 2864110962
LANGUAGE: English DOCUMENT TYPE: Conference Papers
CONFERENCE EDITOR(S): Couvreur, P.; Duchene, D.; Kalles, I.
CONFERENCE SPONSOR: Association de Pharamie Galenique Industrielle
Swedish Academy of Pharmaceutical Sciences
CONFERENCE LOCATION: Paris
CONFERENCE DATE: Feb 1996 (19960) (19960)

14/3,AB/20 (Item 2 from file: 65)
DIALOG(R)File 65:Inside Conferences

00185271 INSIDE CONFERENCE ITEM ID: CN001860690
Cultured Human Sweat Gland Epithelia: Isolation of Glands Using Neutral Red
Fitzpatrick, J. M.; Kelly, J. G.; %Brayden, D. J.%
CONFERENCE: Summer meeting
IRISH JOURNAL OF MEDICAL SCIENCE, 1994; VOL 163; NUMBER 2 P: 99
The Academy, 1994
ISSN: 0021-1265
LANGUAGE: English DOCUMENT TYPE: Conference Abstracts
CONFERENCE SPONSOR: Royal Academy of Medicine in Ireland Section of Biomedical Sciences
CONFERENCE LOCATION: Coleraine
CONFERENCE DATE: Jun 1993 (199306) (199306)

14/3,AB/21 (Item 3 from file: 65)
DIALOG(R)File 65:Inside Conferences

00185267 INSIDE CONFERENCE ITEM ID: CN001860653
Classic Ussing Chamber: Diltiazem Transport Across Rat Colon Epithelium
%Brayden, D. J.%; Dunne, J.; Baird, A. W.; Kelly, J. G.
CONFERENCE: Summer meeting
IRISH JOURNAL OF MEDICAL SCIENCE, 1994; VOL 163; NUMBER 2 P: 97
The Academy, 1994
ISSN: 0021-1265
LANGUAGE: English DOCUMENT TYPE: Conference Abstracts
CONFERENCE SPONSOR: Royal Academy of Medicine in Ireland Section of Biomedical Sciences
CONFERENCE LOCATION: Coleraine
CONFERENCE DATE: Jun 1993 (199306) (199306)

14/3,AB/22 (Item 4 from file: 65)
DIALOG(R)File 65:Inside Conferences

00063834 INSIDE CONFERENCE ITEM ID: CN000641261
Traditional Ussing Chamber: A Poor In Vitro Model for Drug Transport Studies Across Epithelial Cells
%Brayden, D. J.%; Kelly, J. G.
CONFERENCE: Methods to overcome biological barriers in drug delivery-Symposium
KUOPIO UNIVERSITY PUBLICATIONS A PHARMACEUTICAL SCIENCES, 1993; NO 10 P: 62
Kuopio University, Department of Pharmaceutical Technology, 1993
ISSN: 1235-0478 ISBN: 9517805489
LANGUAGE: English DOCUMENT TYPE: Conference Extended abstracts
CONFERENCE EDITOR(S): Urtti, A.
CONFERENCE SPONSOR: University of Kuopio Department of Pharmaceutical Technology Center for Training and Development
CONFERENCE LOCATION: Kuopio, Finland
CONFERENCE DATE: Aug 1993 (199308) (199308)